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Abstract
Preexposure prophylaxis (PrEP) is an innovative biomedical approach that has been used
over the past 6 years to avert the spread of human immunodeficiency virus (HIV). Underprescribing of PrEP could increase the probability of HIV exposure among
serodiscordant couples/partners and those who do not practice safe sex. Previous PrEP
research has not assessed the association between awareness of PrEP, years of experience
of providers, provider types, and the frequency of PrEP prescription among physicians.
Precaution adoption model framed this study, which aimed to evaluate the bond between
the independent variables relating to awareness of PrEP, years of experience, and
provider types with the outcome of the frequency of PrEP prescription among physicians.
A cross-sectional design was applied to survey 100 physician participants. Kendall's taub correlation test and Fisher’s exact test were used to analyze the research questions.
Eighty-seven percent of the surveyed physicians had low awareness about PrEP, and 90%
never prescribed PrEP. Lack of awareness was the primary barrier to prescribing PrEP at
the providers’ level. Kendall's tau-b correlation test showed that higher awareness of
PrEP and years of experience were associated with the frequency of PrEP prescription at
95% confidence interval. However, Fisher’s exact test showed an insignificant difference
between provider types and the frequency of PrEP Prescription. These findings support
the notion that independent of specialty, the more physicians know about PrEP and the
more years of experience they have, the more they prescribe it. The results and
recommendations could enhance positive social change by providing information to
develop an inclusive PrEP education curriculum for health care professionals.
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Chapter 1: Introduction to the Study
Introduction
The human immunodeficiency virus (HIV) is still among the top three public health
concerns in the United States (Centers for Disease Control and Prevention [CDC], 2013a).
Despite the large amounts of money and steady effort put into research and prevention programs,
the United Stated registers 50,000 new HIV cases yearly (CDC, 2013a). HIV preexposure
prophylaxis, (PrEP) is a revolutionary, novel biomedical intervention in the last 6 years. For
different reasons, using PrEP to prevent HIV makes sense (World Health Organization, WHO,
2013). For example, antiretroviral therapy (ART) has 96% efficacy against HIV transmission to
the uninfected people who are at higher risk. These individuals include serodiscordant partners,
men who have sex with men (MSM), needle-sharing drug users and sex workers (CDC, 2013a;
Rosenthal et al., 2013; Wade, et al., 2013). However, Cairn (2013) reported that physicians do
not prescribe PrEP very often in some geographic areas because they lack information about it.
In this chapter, I first present background information, including ignorance about and
barriers to using PrEP, conflicting perceptions about PrEP, the high cost of PrEP and health
insurance, and the need for further PrEP studies. Then I cover the following topics: problem
statement, the purpose of the study, research questions and hypotheses, theoretical/conceptual
framework for the study, its nature, definitions, assumptions, limitations, scope, and
delimitations, and the significance.
Background
According to Cairns (2013), Truvada, the primary PrEP medication is underprescribed in
the United States since its approval in 2012 by the U. S. Food and Drug Administration (FDA).
PrEP has been presented to be operative in preventing HIV among HIV-negative populations
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(CDC, 2013a; Rosenthal et al., 2013; Wade et al., 2013). Only 2,000 doses were prescribed
nationally in 2013, and less than 1% was used for prophylactic purposes. Cairns showed that
among authorized PrEP prescribers, only 37% prescribed it. This underprescription could have
been due to a lack of knowledge about PrEP it.
Ignorance About, and Barriers to, PrEP
People who are exposed to HIV and therefore need PrEP are not only unaware of being
exposed but are also unaware of existing PrEP services. Many people in serodiscordant
relationships are unaware of PrEP (Mijiti et al., 2013). A study in Xinjiang, China, showed that
97.2% of participants (all of whom were in serodiscordant relationships) had never heard about
PrEP (Mijiti et al. 2013). Brooks et al., (2011) ran a semistructured qualitative research study and
identified three barriers to PrEP: excessive cost, fear of side effects, and fear of the need for
lifetime use. Brooks et al. also identified two factors that recommend PrEP: freedom from having
to use condoms and freedom from fear about HIV infection. There is a significant link between
awareness about PrEP and a higher desire to use PrEP (Young, Li, & McDaid, 2013). More than
70% of HIV specialists are likely to prescribe PrEP if they have a positive perception of it (Puro,
Palummieri, De Carli, Piselli, & Ippolito, 2013).
Conflicting Perceptions About PrEP
Puro et al. (2013) stated that there are conflicting attitudes towards, and
perceptions about PrEP. Some patients believe that HIV specialists are more likely than
primary care providers to prescribe Truvada for HIV treatment of HIV-positive patients
(Cairns, 2013). Others believe that HIV specialists are less likely than primary care
providers to prescribe Truvada to prevent HIV in HIV-negative populations (Cairns,
2013). Some public health promoters assume that the underprescription of PrEP is
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because providers believe that PrEP is toxic and that patients would prefer behavioral
interventions to biomedical interventions (Cairns, 2013; Puro et al., 2013). Thus, there is
a significant association between the undesirable attitudes towards prescribing PrEP and
the misinformation about PrEP.
High Cost of PrEP and Health Insurance
According to Horberg and Raymond (2013), the cost of PrEP and its coverage by health
insurance are factors that influence providers’ decisions to prescribe it. They stated that the high
cost of PrEP can dissuade its prescribers and users. PrEP-related expenses include medications,
laboratory, and professional fees. Some indirect costs are those related to the providers’ training
and treatment of adverse drug events. In their study, Horberg and Raymond estimated the total
cost for the first year of HIV PrEP for private funders was over $17,000. Private insurance
companies cover HIV PrEP that their associates have prescribed (i.e., providers with whom they
are in a care management partnership). Their study also revealed that, under the Affordable Care
Act, PrEP coverage varies accordingly to the available qualified health insurance plans. The
Ryan White program, a government health care initiative that helps with the cost of medication
covers HIV medication only for HIV-positive individuals. Other public health coverage
programs, including Medicare, and Medicaid, the leading coverage programs for HIV
prescriptions in the United States, do not cover PrEP. Exploring the cost of PrEP and its
coverage issues in depth in further studies is desirable.
Further Studies on PrEP
First, many global health organizations recommended research on HIV prevention, and
vaccines. These international institutions include United Nations International Children's
Emergency Fund, United Nations Program on HIV/AIDS, WHO, and CDC (WHO, 2013a). All
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of these organizations agreed that the time had come to promote universal accessibility to HIV
prevention and treatment services. Second, further studies are needed to detect gaps in PrEP
provision. Further studies could address the following topics: PrEP implementation technical
problems, barriers to prescribing PrEP, compliance with the PrEP regimen, the conflicting
relationship between PrEP and the use of condoms, PrEP ethical issues, PrEP and HIV law, and
policy. These studies are necessary to address gaps in the integrated treatment and prevention
approach to HIV (Treatment Action Group (TAG), 2013). Third, counseling and educational
interventions are essential to boost efforts to publicize PrEP (Brooks, et al., 2011). Fourth,
detailed HIV PrEP guidelines need to be developed to improve physicians’ readiness to provide
PrEP and behavioral interventions to people at risk for HIV infection (Puro, et al., 2013). That
said it was apparent that multisector studies of PrEP could provide insights to improve its
implementation. These studies could target clinical, social, economic, cultural, and policy
implications (Albert, Warner, & Hatcher, 1998).
Problem Statement
Individuals who refuse to practice abstinence or use condoms, persons in serodiscordant
relationship, and sex workers also belong to the population at higher risk for HIV infection
(Albert, Warner & Hatcher 1998; Civic & Wilson, 2013). Even though some health insurance
companies cover HIV PrEP (Hoberg, 2013; Liu, et al., 2014), physicians are reluctant to
prescribe it (Krakower & Mayer, 2013). What remains unknown is why.
Purpose of the Study
This survey study was an attempt to investigate the barriers to prescribing HIV PrEP and
the need for education among care providers in the Quad Cities in Illinois and Iowa. I examined
how researchers could use HIV PrEP awareness, providers’ years of service, and provider types
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as predictors of the frequency of PrEP prescription among care providers. A better understanding
of the knowledge, behavior, and attitudes of physicians regarding the PrEP will better indicate
where additional education may be needed. Three independent variables (awareness of HIV
PrEP, the number of years of service as a primary care provider or HIV specialists, and provider
type), and one outcome variable (frequency of PrEP prescription) were analyzed to test the
hypotheses.
Nature of the Study
Study Variables
The outcome variable or dependent variable in this study was the frequency of PrEP
prescription. The independent variables included HIV PrEP awareness, the number of years of
service as a primary care provider or HIV specialist, and the difference between provider types.
The three independent variables were split into multiple levels (i.e., dummy variables), and there
was only one dichotomous outcome variable (i.e., the frequency of PrEP prescription: low versus
high). These conditions justified the applicability of the logistic regression analysis to this study.
I also included some secondary variables (i.e., covariates) such as gender (i.e., male versus
female), geographic location (i.e., Iowa versus Illinois) and HIV specialist versus a non-HIV
specialist. I used SPSS software to analyze the data. Multiple logistic regression (regression on
dummy variables), analysis of variance (ANOVA) and analysis of covariance were used to
answer the hypotheses. Logistic regression was suitable to examine whether there was a
difference between provider types (i.e., family practitioners, pediatricians, internists,
obstetricians/gynecologists, and infectious disease/HIV specialists) and the outcome variable
(i.e., the frequency of PrEP prescription). Researchers use logistic to assess the internal variance
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within the research population groups as opposed to the difference between them (CERG
Resources, n. d.).
Study Design
I used a cross-sectional design to explore whether there is an association between the
independent variables and the outcome variable. Cross-sectional design helps inquirers to
establish a relationship between the research variables. It also offers an opportunity to select
random participants who provide representative data to explain the study variables (FrankfortNachmias & Nachmias, 2008). The cross-sectional design fit this quantitative study that
generated numerical and broad data to describe the research problem. The quantitative methods
help the researcher to describe the relationship between the study variables through statistical
analysis (Creswell, 2009).
I designed my survey, so I needed to pilot test my survey instrument. A minimum of
eight returned surveys was desirable (i.e., 42.11% response rate) to accept the result as valid. To
do so, I selected 10% of my 185 estimated sample size including the primary care providers and
HIV specialists to participate in the pilot test. In essence, I needed 19 participants for my pilot
study. I also needed a minimum of 78 returned surveys corresponding to 80% confidence
interval to accept the results of the actual study as valid. My plan to reach that goal was to
increase the sample size. I started the survey with 185 participants (i.e., 119 corresponding to
95% power increased by 54%). The breakdown was 74 family practitioners, 21 pediatricians, 57
internists, 18 obstetricians/gynecologists, and 15 infectious disease / HIV specialists. The
calculated sample size was 119 for 95% power to which I added 54% to increase the response
rate (Table 2). I added the 15 of the 17 physicians from the infectious disease subpopulation to
which proportional sampling was not applied to have N = 185. I excluded the pilot test
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participants from the actual study to avoid the sampling related biases. I collected data through
self-administrated paper-based survey questionnaires. The pilot test step was vital to ensure the
validity of the survey instrument before the actual study data collection.
Research Questions and Hypotheses
Three research questions and their allied null and alternative hypotheses guided this
study.
Note that provider type is an independent variable composed of five dummy variables:
family practitioners, pediatricians, internists, obstetricians/gynecologists, and infectious
disease/HIV specialists.
Research Question 1: What is the association between HIV PrEP awareness and the
frequency of PrEP prescription among primary care providers and HIV specialists in the QuadCities?
Ho1: There is no association between HIV PrEP awareness and the frequency of
PrEP prescription among primary care providers and HIV specialists in the Quad-Cities.
Ha1: There is an association between HIV PrEP awareness and the frequency of
PrEP prescription among primary care providers and HIV specialists in the Quad-Cities.

Research Question 2: What is the association between the number of years of service as a
primary care provider or HIV specialist and the frequency of PrEP prescription among primary
care providers and HIV specialists in the Quad-Cities?
Ho2: There is no association between the number of years of service as a primary
care provider or HIV specialist and the frequency of PrEP prescription among primary care
providers and HIV specialists in the Quad-Cities.
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Ha2: There is an association between the number of years of service as a primary
care provider or HIV specialist and the frequency of PrEP prescription among primary care
providers and HIV specialists in the Quad-Cities.

Research Question 3: What is the association between provider types and the frequency
of PrEP prescription among primary care providers and HIV specialists in the Quad-Cities?
Ho3: There is no association between provider types and the frequency of PrEP
prescription among primary care providers and HIV specialists in the Quad-Cities.
Ha3: There is an association between provider types and the frequency of PrEP
prescription among primary care providers and HIV specialists in the Quad-Cities.

Theoretical or Conceptual Framework
PrEP services have played a significant role in preventing HIV-negative individuals from
HIV infection. Other HIV prevention programs combine behavioral, biomedical, and structural
interventions (Underhill, Operario, Mimiaga, Skeer, & Mayer, 2011). Public health professionals
have identified numerous theoretical frameworks that apply to the HIV prevention field. Many of
those theories like precaution adoption process model (PAPM) are useful to define PrEP-related
concepts.
Developed by Janis and Mann in 1977, PAPM explains the process in individuals’
decisions making and the conversion of the decision into action in seven stages (Glanz, Rimer, &
Viswanath, 2008). The first stage is the unawareness of the health issue phase. In the second
stage, people learn about the problem for the first time but feel not concerned about it. The third
stage, the decision-making phase explains how people are engaged by the health issue, and start
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thinking about the responses. At this point, people can decide to stay at this stage or resolve to do
nothing. This category of people falls under Stage 4 and “halting” PAPM. The third possibility is
to move to the next Stage 5 through precaution adoption. Stage 6, behavior initiation phase,
allows people to acting. The last, Stage 7, is when people maintain their new behavior over time
(Glanz, et al., 2008, p.126).
Lack of information about PrEP is often associated with PrEP underprescription among
care providers (White, Mimiaga, Krakower, & Mayer, 2012). The focus of this study was to
explore HIV/AIDS health-protective behaviors by determining how primary care providers and
HIV specialists make decisions to prescribe PrEP and how they translate their decisions into
actions. For this reason, it was appropriate to adopt the PAPM as a theoretical framework and the
concept of implementation intentions to guide this study.
PAPM allows inquirers to identify the stages that people go through when they start
“health protective behaviors” (Glanz, et al., 2008). It also provides indicators that help
researchers to determine the factors favoring behavior change from one stage to another (e.g.,
from awareness to action). The model allowed me to identify barriers to PrEP provision at each
stage. See the adapted visual representation of the model (Figure 1) bellow.
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Stage 1
Never hear
of HIV
PrEP
(Unaware)

Stage 2
Aware of
HIV PrEP,
not engaged
in PrEP
service (Low
perceived
susceptibility
)

Stage 3
Deciding
about
Prescribing
PrEP

Stage 5
Have
decided to
Prescribe
PrEP

Action
Implementati
on intention
intervention
(following
through
where & how
of PrEP
prescription)

Stage 6
Prescribed
PrEP

Barriers to HIV PrEP
Prescription
Being aware, years of
experience & being a
primary care provider
vs. an HIV specialist

Pre-Action
Prescription
intention
(Where and how to
get PrEP
information:
Education needs)

Stage 4
Have decided
not to
prescribe PrEP
(low perceived
susceptibility)

Figure 1. Visual representation of PAPM constructs showing the relationship between
implementation intentions concept and the gaps in HIV PrEP Prescription. Adapted from
“Integrated Precaution Adoption Process Model and Implementation Intentions Concept Applied
to Breast Cancer Screening,” by K. K. Engelman, A. P. Cupertino, C. M. Daley, T. Long, A.
Cully, M. S. Mayo, E. F. Ellerbeck, M. V. Geana, & A. Greiner, 2011, Engaging diverse,
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underserved communities to bridge the mammography divide. Copyright 2011 by Engelman et
al., licensee BioMed Central Ltd.
Applying Gollwitzer’s (2006) implementation intentions concept to this study helped me
examine how PrEP service implementation intentions can enhance the primary care providers
and HIV specialists’ willingness to prescribe it. The implementation intentions are a goaldirected behavior where people perform behavior B if they met a condition C (Gollwitzer &
Sheeran, 2006). The concept is effective in enhancing past behavior that leads to the prediction
of new behavior (Orbeil, Hodgldns, & Sheertan, 2014). If it is applied, the concept can help
primary care providers and HIV specialists to meet their PrEP prescription goals. Gollwitzer
(n.d.) explained the concept as a motivation driver for individuals to adopt healthy behavior. The
connection between the study variables and precaution adoption process model constructs is
presented in Table 1.
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Table 1
Linkage Between PAPM Constructs and Study Variables
PAPM

Independent variables

Outcome

constructs

Stage 1:

variable
HIV PrEP

Number of years

Difference

Frequency of

awareness

of service

between provider

HIV PrEP

type

prescription

Never heard

Unaware of Issue of HIV PrEP

As a factor

As a factor

leading to that

leading to that

situation

situation

Stage 2:

Never thought

As a factor

As a factor

Unengaged by

about prescribing

leading to that

leading to that

issue

HIV PrEP

situation

situation

As a factor

As a factor

Stage 3:
Undecided about

Undecided

leading to that

leading to that

acting

about prescribing

situation

situation

Do not want to

As a factor

As a factor

Do not want to

prescribe HIV

leading to that

leading to that

act

PrEP

situation

situation

HIV PrEP
Stage 4:

(Table continues)
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PAPM

HIV PrEP

Number of years

Difference

Frequency of

constructs

awareness

of service

between provider

HIV PrEP

type

prescription

Stage 5:
Decided to Act

Stage 6: Acting

As a factor

As a factor

Plan to prescribe

leading to that

leading to that

HIV PrEP

situation

situation

Prescribing HIV

As a factor

As a factor

PrEP

leading to that

leading to that

situation

situation

Stage 7:

Prescribing HIV

As a factor

As a factor

Maintenance

PrEP

leading to that

leading to that

situation

situation

Definition of Terms
Antiretroviral therapy (ART): It consists of the use of the retroviruses inhibitors drugs to
treat HIV. It is also known as highly active antiretroviral therapy (AIDS info, 2008). ART
combines three or more HIV drugs that act on different stages of HIV life cycle (AIDS info,
2008).
Biomedical interventions: HIV prevention techniques, biomedical interventions consist
of the use of clinical, medical, and public health prevention methods to reduce physiologically
and biological risk factors for HIV infection (Effective Interventions, 2012). They help to
decrease HIV infectiousness, to prevent HIV infection, and to reduce susceptibility to HIV
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(Effective Interventions, 2012). In addition to the vaccine, preventive treatments and males’
circumcision, the biomedical interventions include sexually transmitted infections (STIs)
treatment and diaphragm use (Mayer, Margie Skeer, & Mimiaga, 2010).
HIV preexposure prophylaxis (PrEP): It is HIV drug-based preventive intervention that
allows HIV-negative persons who are vulnerable to HIV infection to use antiretroviral drugs like
Truvada to reduce HIV transmission risks (AIDS info, 2008).
Primary care providers: Health care practitioners, primary care providers play a medical
caring role in the community by offering preventive care and healthy lifestyle education services
to their patients (MedlinePlus, 2014). Their primary tasks are to diagnose and treat common
medical conditions and refer clients to specialists as needed (MedlinePlus, 2014). Primary care
providers include physician assistants, nurse practitioners, family practitioners, internists,
pediatricians and obstetricians/gynecologists
Serodivergent relationship: The concept describes the situation where an HIV-negative
person is in sexual relation with his or her HIV-positive partner. The other terms that describe
these kinds of relationships include serodiscordant, discordant, magnetic or HIVpositive/negative (AIDS.gov, 2012).
Assumptions
Although the FDA has approved PrEP drugs like Truvada, PrEP for HIV prevention was
underprescribed by physicians in the Quad Cities area. I assumed that awareness about PrEP, the
number of years in the medical field, and provider types have an influence on PrEP prescription
in the Quad Cities. As a result, there was a need for a quantitative study to explore the barriers to
PrEP prescription.
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Proactively, it is important to foresee additional HIV PrEP education for primary care
providers and HIV specialists in the Quad Cities area. The data that I collected were from
doctors. Data from assistant physicians and nurse practitioners might not reflect their attitudes
regarding PrEP prescription because they work under the supervision of others doctors.
Scope and Delimitations
In this study, I focused on PrEP prescription effectiveness in the Quad Cities
Illinois/Iowa. The barriers to prescribing PrEP were assessed at the physicians’ level only. I
delimited the research to a quantitative, cross-sectional study design. The study participants were
family practitioners, pediatricians, internists, obstetricians/gynecologists, and infectious
disease/HIV specialists, who were practicing. They must live in the geographic area of 70 miles
radius from Rock Island city in Illinois as of May 15th, 2015. I excluded physician assistants and
nurse practitioners from this study. The independent variables were limited to the PrEP
awareness, the number of years of service as a primary care provider or HIV specialists, and
provider’s type. The unique outcome variable in this study was the frequency of PrEP
prescription. The study included some demographic variables like gender, age, and geographical
location (living in Iowa versus Illinois or urban versus rural). Race and religious beliefs were
other independent variables that could be used in this study, and therefore could be considered
exploratory in nature in explaining the lack of PrEP prescription among care providers.
However, they were excluded to keep the study simple.
I chose the word barriers over causes and knowledge for two reasons. First, the word
barrier aligns to the research problem. The study was about identifying the factors that can
explain HIV PrEP under prescription at the prescribers’ level to recommend further educational
action. Second, using the word cause would only be appropriate in an experimental study. In this
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cross-sectional survey study, I only explored the association between variables. Therefore, it was
not appropriate to investigate the cause and effects relationship in this study. Furthermore, the
word knowledge gives readers the impression that I focused on HIV PrEP prescription awareness
only. In the title, I preferred the expression HIV PrEP to the name Truvada because Truvada is a
component of PrEP. Moreover, Truvada has both treatment and preventive functions whereas
PrEP is a prophylaxis procedure. Prevention is the best strategy to limit HIV infection (Mayer, et
al., 2010). Thus, using PrEP helped me to narrow the study to HIV prevention among HIVnegative populations that are highly exposed to HIV infection.
Limitations
Some intentional and unintentional biases can raise questions regarding the ability of
one’s research to provide valid and trustful results (Creswell, 2009). The potential biases in this
study that I was working on included the following:
1- Participant selection (i.e., there are fewer HIV specialists in the research geographic
area than other groups that fall under primary care specialties). This type of bias can
create an underrepresentation of HIV specialists in the study sample population. I
used a proportional sampling method to avoid the participant selection bias.

2- It is also possible to perceive PrEP for certain subpopulations more than others or
assuming that HIV specialists are better off in terms of PrEP awareness and prescribe
more PrEP than other primary care providers. Being aware of that allowed me to be
careful while interpreting and analyzing data.
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3- Nonresponse and low participation rates could be potential threats to my research
validity. I increased my sample size by 54% to mitigate that problem. Soriano (2013,
p. 91) suggested an increase in the research population sample size by 43% as a
solution to low participation rates issue in a study. I selected 185 then increased that
to 300 subjects for my study. Developing understandable survey instruments can help
to reduce nonresponse

4- Biases can also arise from researcher’s experience. I examined some research
parameters like PrEP prescription or low PrEP literacy as good or not because of my
background in HIV/AIDS field. Being aware of the problem alerted me to be neutral.
I interpreted and concluded on the study results and findings based on the outputs
from valid and reliable data collection instruments and statistical tests only.

5- The perceived efficacy of PAPM to conceptualize PrEP awareness and provision
could constitute a theory bias in the study. Sampson Jr., (2012) acknowledged theory
bias in a study when one perceived the efficiency in certain constructs to
conceptualize research problems. I worked closely with my chair and committee
members to minimize all theory related biases.
Significance
PrEP is an HIV prevention biomedical intervention within the primary health care setting,
as opposed to specialized care. The rate of new HIV incidences is still alarming inside and
outside of the United States (Krakower & Mayer, 2012). Since HIV is still rampant in the world,
addressing tailored educational and training needs of health care providers in primary health care
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settings becomes a must. The results and findings of this study could provide CDC and other
international public health organizations like WHO with valuable information to develop
detailed guidelines for PrEP education and service. Various insights from this study could help
providers determine effective PrEP guidelines and related services, and in turn, limit the risk of
HIV proliferation in the community. The study could inspire public health practitioners to
develop a suitable education approach to improving PrEP literacy among health care providers.
Educating people about PrEP is vital to arose positive social change regarding stimulating a
universal access to PrEP services. This study also helped to understand how and why primary
care providers and HIV specialists underprescribed PrEP in the studied geographic area. I
explored the lack of PrEP prescription contributing factors like low PrEP literacy, the number of
years of service in the medical field and provider types. Finally, the findings and
recommendations provided insights to improve HIV/AIDS policies.
Summary
The lack of funding for antiretroviral and the difficulty of monitoring HIV PrEP clients
were some barriers to HIV PrEP prescription among HIV specialists (Puro et al., 2013). The
information above was a benchmark against which I compared the study results based on the
information that I collected from primary care providers and HIV specialists. Combined with
other behavioral interventions, when it is suitable, PrEP reduces the risk of HIV infection in
HIV-negative populations. For this reason, consistent efforts should be made to enhance HIV
PrEp prescription among HIV specialists and primary care providers (Golub, Gamarel, Rendina,
Surace, & Lelutiu-Weinberger, 2013). In this research, I examined the association between HIV
PrEP awareness, the number of years of service as a primary care provider or HIV specialist,
provider types and the frequency of PrEP prescription.
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In Chapter 2, I discuss existing peers review literature on HIV PrEP, literature search
strategies and HIV PrEP-related issues and concepts. Following the literature review, I describe
the research methods in Chapter 3, present the research findings in Chapter 4, and in Chapter 5,
go over the discussion, inferences for social change, and proposed the recommendations for
future study.
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Chapter 2: Literature Review

Introduction
Essential to this research is the concept that people perform behavior B if they met a
condition C (Gollwitzer & Sheeran, 2006). There are the plethora of studies of HIV epidemics as
well as studies of approaches that have been applied to mitigate its occurrence (CDC, 2011). The
combination of the behavioral and biomedical interventions is a successful evidence-based
approach of controlling HIV propagation (CDC, 2011). However, the education based on
abstinence and condom use only has shown its limits in reducing the risks of HIV infection
(CDC, 2013b). PrEP regimen is recommended to HIV-negative people who might be at higher
risk for the HIV infection like serodivergent couples/partners (AIDS.gov, 2012). Many studies
and publications have contributed to HIV PrEP-related literature in the last 6 years. The purpose
of this literature review is to explore various studies on PrEP to inform the background of my
research topic and identify gaps in the literature. I highlight the gaps upon which this study was
designed to justify the conduct of this study to the reader.
Literature Search Strategy
The key terms that I used for the web search entry included HIV pre-exposure
prophylaxis, HIV PrEP, HIV PrEP guidelines,and Truvada prophylaxis HIV (Duncan &
Duncan, 2012). I also used PrEP Prescription, HIV PrEP prescription frequency, HIV PrEP,
cost and insurance, and HIV PrEP Literacy for internet search. I searched literature through
many Walden University Library databases such as Medline, Academic Search Alumni
Edition, Journal of American Medical Association, Pubmed, and Health Sciences: An SAGEFull Text Collection and CINAHL Plus. Google Scholar allowed me to search for PrEP fact
sheets and scholarly articles. The CDC and the WHO websites provided me additional
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information resources to explore official PrEP guidelines and protocols. They allowed me to
explore studies, conference reports, and other publication on PrEP. I filtered the search by peer
review articles after the publication date of 2010.
Literature Review on the Concepts and Key Variables
Understanding PrEP
PrEP is an HIV prevention regimen for HIV-free persons prone to ongoing substantial
“risk of HIV infection” (Aids.gov, 2014). It consists of one pill of Truvada daily as a preventive
measure to reduce HIV transmission risks (AIDSinfo, 2008). Truvada is “a combination of
emtricitabine and tenofovir disoproxil fumarate,” both belonging to the HIV nucleoside reverse
transcriptase inhibitor drugs that stop HIV from making copies. Its dosage for PrEP requires
“200 mg of emtricitabine and 300 mg of tenofovir disoproxil fumarate” in a single pill
(Choopanya et al., 2013). Truvada can be (a) used with other antiretroviral drugs to treat HIVpositive patients and (b) used alone to prevent HIV infection in HIV-negative populations. When
taken consistently, it has decreased the risk of HIV transmission among HIV-negative
populations (Choopanya et al., 2013). Truvada is a component of PrEP that is a routine
procedure. PreP regimen has four implementation phases. The first consists of assessing
significant risk for HIV infection. The second is about establishing PrEP candidates’ eligibility
clinically (i.e., documented HIV-negative status, documented hepatitis B virus
infection/immunization status, and checking for (a) no contraindicated medication, (b) no signs
of severe HIV infection, and (c) healthy liver and good functioning kidneys). The third consists
of prescribing Truvada (a steady oral dose of Truvada on the daily basis). The fourth is a followup. The follow-up services include every 3 months or 6 months for HIV and STI tests,
counseling for medication adherence, renal function assessment, pregnancy test for females,
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clean needles/syringes exchange, and substance abuse treatment services (Smith, 2014). The
CDC recommended PrEP in addition to the following:
-

Consistent and correct use of condoms,

-

Getting tested periodically for HIV and sexually transmissible diseases,

-

Adopting less risky sexual behaviors, and

-

Using sterilized drug injection equipment or participating in a drug treatment program
(Aids.gov, 2014).

Effectiveness and Awareness of PrEP
Every new drug has to be proven safe and effective before its commercialization (FDA,
2014). The effectiveness of HIV PrEP is a point of debate, with many misconceptions about its
implementation (Wade et al., 2013). Because understanding PrEP regimen related issues are in
flux, it is important to update readers on the current publications and studies of the HIV PrEP.
Choopanya, et al. (2013) found tenofovir disoproxil fumarate effective to reduce HIV infection
risks down to 49%, (95% CI, 9.6 to 72.2; p = 0.01). Paltiel et al. (2009) conducted a cohort study
on the effectiveness of PrEP among MSM in the United States. The study provided data for a
computer-stimulated HIV infection and care as an archetype of PrEP. The results showed PrEp
effective to decrease the risk of HIV infection up to 19% down and to improve patients’ mean
life expectancy by 0.8% (Paltiel, et al., 2009).
Care providers should know more about HIV PrEP (Rosenthal, et al., 2013). White, et al.
(2012) conducted two successive online survey studies separated by 4 month period interval with
N = 178 and N = 115 respectively for the physicians in Massachusetts. The results showed an
increase from 79% to 92% (p < 0.01) of HIV PrEP knowledge among care providers. Up to 96%
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of the surveyed physicians believed that formal PrEP guidelines from CDC would increase their
readiness to prescribe PrEP (White, et al., 2012). The problem of PrEP unawareness has crossed
the United States’ borders. Rosenthal et al. (2013) conducted a cross-sectional study of HIVpositive clients to assess PrEP awareness level of the physicians in France. The study targeted 23
representative infectious diseases and internal medicine departments. Only 41.8% of the
surveyed people aware of the PrEP, and about 8.3% declared that they had discussed PreP
information with their friends and relatives (Rosenthal et al., 2013). Duncan and Duncan (2012)
found Google.co.uk and Bing to be popular search websites where people have access to HIV
PrEP information. In this section, I covered HIV PrEP effectiveness and its awareness level
among potential PrEP candidates and physicians, which had not been linked to reporting in the
literature for the Quad Cities in Illinois.

Challenges of Prescribing PrEP
Prescribing PrEP could be challenging to some care providers because of the divergent
view on it (Puro et al., 2013). HIV specialists have different attitudes towards and insights
regarding prescribing PrEP (Puro et al., 2013). In 2012, Puro et al. conducted a survey study
with N = 311 of HIV specialists selected through a convenience sampling method to explore HIV
specialists’ attitudes and perceptions about prescribing PrEP in Italy. They used participants’
readiness to prescribe PrEP as a criterion to classify them into two groups (i.e., people who have
positive and those who have negative views about PrEP). They applied univariate and
multivariate regression analysis to assess the relationship between different attitude towards
PrEP prescription and certain factors. The results illustrated the contradictory attitudes towards
PrEP prescription among care providers. For example, 70% of the surveyed physicians had
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optimistic attitudes towards PrEP and were willing to prescribe it. On the another hand, 30% had
a negative view about PrEP. Puro et al. also found an association between the insufficient
information, potential toxicity and cost, and underprescription of PrEP. Their study also revealed
an association between the lack of provision of information, concerns about toxicity, lack of
formal guidelines, and the positive or negative attitudes of HIV specialists towards PrEP
prescription.
Providers did not prescribe PrEP to their patients very often in the United States.
Krakower and Mayer (2013) reported in a study that only 4% of participants had prescribed
PrEP. Among 43% of HIV/AIDS specialists, who admitted that they had received HIV PrEP
prescription requests from their patients, only 19% had prescribed it. Before PrEP initiatives,
HIV prevention strategies included condom promotion, perinatal interventions, male
circumcisions, and harm reduction interventions (CDC, 2013a). CDC (2013) remarked that
despite these prevention efforts, the United States experienced around 50,000 new HIV
infections in 2013. PrEP is effective in preventing HIV infection (CDC, 2013a; Rosenthal et al.,
2013; Wade et al. 2013). However, the illiteracy about PrEP can lead to its underprescription
(Castillo, 2013). Many researchers found a substantial association between primary care
providers’ PrEP knowledge and increased PrEP prescription (Kalichman, Ramachandran & Catz,
1999; Young, Li & McDaid, 2013).
Mansergh, Koblin and Sullivan (2012) addressed PrEP implementation challenges for
MSM and their communities. Some of the challenges include misapprehension of PrEP, charges,
possible epidemiological effects, lack of suitable PrEP messaging, and inadequate usage of PrEP.
Jay and Gostin (2012) also published an article that identified many ethical challenges such as
increase of unsafe sex practice, “behavioral disinhibition,” health care disparities due to the high
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cost, and drug dependency associated with HIV PrEP. Naswa and Marfatia (2011) raised the
same concerns about PrEP. Furthermore, Golub et al. (2013) found a significant association
between free access to PrEP and (a) a sense of protection, (b) PrEP acceptance, and (c) PrEP
adherence. Thus, it is imperative to identify and address the challenges appropriately to make
PrEP services affordable.
The above studies did not address PrEP prescription attitudes and perception among
primary care providers who can prescribe PrEP. They also did not include HIV PrEP education
needs. Those gaps in the literature justify the relevance of my dissertation topic.

HIV PrEP Education and Literacy Improvement Needs
Education is the key strategy to enhance PrEP literacy. Krakower and Mayer (2012)
stated that the higher HIV infection incidence rate in the United States requires multilevel
prevention approaches including PrEP education enhancement within care providers. In articles
review study, Krakower and Mayer evaluated primary care providers’ knowledge about PrEP.
They used five indicators (a) attitudes to identify potential PrEP clients, (b) PrEP counseling
skills, (c) PrEP drug monitoring abilities, (d) the level of understanding antiretroviral drug
resistance, and (e) HIV transmission process to assess health care providers’ PrEP literacy level.
The study allowed Krakower and Mayer to portray the need for additional education on HIV
PrEP for the primary care providers. It is important to develop PrEP curricula and programs for
health care professionals and clients to solve HIV PrEP low literacy problem. According to
Jukkala et al. (2009), improving primary care providers’ PrEP use for HIV prevention could
enhance health outcomes, and reduce unnecessary clinical services (Jukkala et al., 2009).
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In addition, the acceptance of PrEP is often associated with the clients’ health literacy
level (Barragán et al., 2005). In a prospective survey study with 372 participants at an urgent
care center, Barragan et al., (2005) evaluated whether there is an association between
participants' health literacy and their readiness for HIV screening. The finding showed that low
literacy level clients were more likely than high literacy level clients to accept HIV testing.
Drainoni et al., (2008) also found that HIV health literacy was vital for both HIV-positive
patients and care providers. Young et al., (2013) conducted a cross-sectional study with 1,515
gay and bisexual men. They explored the relationship between knowledge of and willingness to
use PrEP and readiness to participate in a PrEP research in Scotland. The findings showed a
significant relationship between awareness of PrEP and rose in the clients’ readiness to use PrEP
(Young et al., 2013).
The reviewed literature provides insights for better understanding of HIV PrEP issues. It
contains arguments and empirical data that support the idea of enhancing primary care providers’
HIV health literacy to ensure a smooth transition between the shifts from HIV/AIDS special care
to the primary care settings. However, there are still gaps in the literature regarding the
identification of subsequent research theory that will help to depict PrEP under prescription
behavioral mainstream issues that were not addressed through educational interventions in the
Quad Cities. For that reason, I use PAPM to determine the factors that explain the behavior
displayed by the providers under each of the seven stages of the PAPM regarding their attitude
towards PrEP Prescription.

Guidelines for HIV PrE Prescription
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When used properly, the HIV PrEP regimen can protect people at higher risk of getting
HIV (Scheibe, 2012). Despite this indication, the lack of a PrEP guideline could lead to its
misuse, and the existence of several PrEP guidelines could be confusing and lead to chaos in the
PrEP implementation process. In 2011, the CDC mentioned the lack of a comprehensive PrEP
implementation guidelines and the nonexistence fixed PrEP protocol. Significant data from many
PrEP studies allowed the CDC to develop interim guidance for PrEP prescription to at higher
risk for HIV populations (CDC, 2011; Scheibe, 2012).
PrEP interim guidance developed by CDC (2011) included (a) the necessity to prescribe
HIV PrEP to at higher risk heterosexual adults and (b) the prohibition to prescribe TDF/FTC
(Truvada) as PrEP for HIV-positive clients. The interim guidance also endorsed the mandatory
use of HIV PrEP for serodiscordant couples who planned to have a baby (CDC, 2013a).
Furthermore, the interim guidance encouraged women to prove their pregnancy status through a
documented pregnancy test to be eligible to start the HIV PrEP regimen. It required care
providers to discuss PrEP benefits and risks with women who plan to have a baby before PrEP
initiation. It required a mandatory submission of pregnancy information about PrEP clients to the
Antiretroviral Use in Pregnancy Registry. The guidelines also recommended physicians inform
clients about the Truvada adherence. To PrEP prescribers, reporting PrEP adverse effects to the
FDA's MedWatch is a must (CDC, 2011). The CDC developed PrEP prescription guidance for
MSM population. According to CDC, the regulation requires steady updates as needed.
An updated interim guideline for PrEP, published by the CDC in 2013b, authorized the
institutionalization of PrEP services in intravenous drug users’ services. It also banned PrEP
prescription to individuals who have a creatinine clearance level less than 60 ml/min (CDC,
2013b). Lastly, the updated guidance advises prescribers to target people at “very high risk for
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HIV infection” (CDC, 2013b). It recommended that physicians monitor the behaviors that can
put their clients at higher risk for HIV infection and control their HIV and pregnancy status
routinely (CDC, 2013b).
The WHO, (2012) developed a document that recommended evaluating and grading the
evidence for serodiscordant status among couples or partners before prescribing PrEP to the
potential clients. It suggested HIV PrEP use as additional prevention intervention for the
uninfected partners in the countries where HIV infection arise among serodiscordant
couples/partners (WHO, 2012). Scheibe (2012) also developed an HIV PrEP guideline for
Southern Africa countries. There is a need for further investigations to assess the impact of the
multiple HIV PrEP prescription guidelines on its implementation in the practice.

HIV PrEP and Stigma
People could become refractory to PrEP if they are stigmatized. The effects of stigma on
the use of HIV PrEP were diversely appreciated (Smith, et al., 2012). Smith et al. (2012) stated
that it is crucial to know whether stigma will enhance the status of people who use PrEP or not.
Kenworthy and Bulled (2013) examined the ethical issues surrounding PrEP services in the
developing country (Lesotho). They showed that there were many disparities in the distribution
of PrEP services in the world and that stigma is associated with underprescription of PrEP. HIV
prevention through PrEP initiatives needs effective structural and institutional support to reduce
HIV PrEP-related stigma (Wheelock, et al., 2012).
The frequency of PrEP prescription is distributed disproportionally across the United
States. Cairns (2013) found that physicians in the Northern America prescribe more HIV PrEP
than those living in the Southern America where women benefit the most from PrEP services.
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The reasons that explain these disparities were not assessed in the Cairns’ study. However, the
study is of an inspirational relevance for further researches on PrEP.
Promoting PrEP could have an undesirable impact on other HIV prevention behavioral
interventions such as abstinence and the use of condoms and vice versa. Wade et al., (2013)
developed the key themes that could assist researchers while investigating the impact of the
behavioral interventions on HIV PrEP. The themes included (a) the motivations to use PrEP, (b)
barriers to PrEP use, (c) facilitators to PrEP use, (d) sexual decision-making in the context of
PrEP, (e) prospective PrEP education content, and (f) perceived effective characteristics of PrEP
delivery personnel (Wade, et al., 2013). These themes could be adapted as a survey instrument to
assess patients’ willingness to accept PrEP and or providers’ readiness to prescribe it. Golub et
al., (2013) showed that more than 55% of the surveyed MSM and transgender women were
ready to use PrEP services. Numerous are the studies that investigated PrEP awareness,
acceptance and use within diverse populations. Those studies targeted MSM, serodiscordant
couples/partners, sex workers, and needle-sharing drug users (CDC, 2013d; Rosenthal et al.,
2013; Wade et al., 2013). However, none of the studies has explored PrEP literacy among
primary care providers, and HIV specialists. More specifically, no research that targeted primary
care providers and HIV specialists had been done to assess their PrEP prescription frequency in
the Quad Cities Area in the United States.
Literature Review on the Theoretical Foundation
The PAPM has been applied to many studies in the public health field. Glanz, Rimer, &
Viswanath, 2008 cited several studies that used PAPM. For example, they mentioned Blalock,
DeVellis, Giorgino et al. (1996) who applied PAPM to their prevention of osteoporosis study.
They also cited Clemow, Costanza, Haddad et al. (2000) who used PAPM as a theoretical
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framework for their study of mammography issues. They finally give credit to Weinstein &
Sandman (2004) who adopted PAPM in a study of home radon testing problems. Costanza et al.,
(2007) also used PAPM in a colorectal cancer study. It was applied to a comprehensive sexual
education study (Stanger-Hall, 2011) and to a cyberbullying study (Chapin, 2014). The PAPM
has also been used for modeling HIV prevention efforts (Jacobson, 2010), preventing HIV in the
aging population (Jacobson, 2010), and explaining HIV serodiscordant experiences (Lelaka,
2014). Most of the studies that used PAPM have generated quantitative cross-sectional data
(Block et al. 1996; Chapin, 2014; Costanza, et al. 2007; & Lelaka, 2014). The literature review
provided additional evidence for why PAPM theory was a good choice for this study.
Literature Review on the Methods Used in Previous PrEP Studies
Among all research methods, the quantitative cross-sectional survey has been the most
applied to the studies on HIV PrEP (Duffus, 2011 & Whiteside, Harris, Scanlon, Clarkson,
2014). Whiteside, et al. (2014) used a cross-sectional design to examine “the self-perceived risk
of HIV and attitudes about PrEP” in STD clinics in South Carolina (United States). They
recruited 405 clients by using convenience-sampling methods. They gave a $20 gift card as an
incentive to each surveyed person upon the survey completion. Furthermore, they used SAS
version 9.2 to treat the research data and a multivariable logistic regression model to analyze the
effect of the demographic variables on the participants’ attitudes about PrEP. Finally, they used
ordinal logistic regression models to assess the differences in PrEP perceptions among different
groups. Leonardi, Lee, and Tan, (2012) used a survey approach to examine awareness of PrEP
and the participants’ preparedness to use HIV PrEP in Toronto, Canada. They collected data
from 256 participants, recruited on the voluntary basis, through self-administered questionnaires.
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They run several statistical analysis tests including exploratory logistic regression models,
multivariate logistic regression model, and the multivariate model.
This literature review explored HIV PrEP effectiveness and awareness, HIV PrEP
prescription and challenges, HIV PrEP education and literacy improvement needs, guidelines for
PrEP prescription, and HIV PrEP stigma. I examined some studies and articles related to the
PAPM, the theoretical framework of this study. I also reviewed the methods applied to other
HIV PrEP studies.
It appeared that none of the reviewed articles and texts discussed how awareness of PrEP,
providers’ years of experience and provider types influence the frequency of PrEP prescription
among primary care providers and HIV specialists in the Quad Cities. This study scrutinized
whether there is an association between the independent variables and the outcome variable. The
results helped me to justify the following assumptions:
1. The more providers know about HIV PrEP, the higher frequency of PrEP prescription
will be.
2. The more years of experience providers had, the higher frequency of PrEP
prescription will be.
3. Being a primary care provider versus HIV specialist may increase the frequency of
PrEP prescription.

Summary and Gaps in the Literature
The existing literatures that have explored HIV PrEP intervention present the fact that
PrEP is effective (CDC, 2013; Wade, Mayer, Elsesser, Mimiaga, O'Cleirigh, & Safren, 2013).
The literature review also revealed that awareness about PrEP could lead to its prescription
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among physicians (Krakower, & Mayer, 2012). There were three of the studies that examined
HIV PrEP underprescription problems (Cairns, 2013; Golub, Gamarel, Rendina, Surace, &
Lelutiu-Weinberger, 2013; Krakower & Mayer, 2013). Other studies demonstrated that HIV
PrEP acceptance is often associated with people’s health literacy level.
Evidence from the literature revealed that no study investigated the frequency of HIV
PrEP prescription among primary care providers, nor assessed the barriers of HIV PrEP
prescription at primary care providers’ level exclusively in the Quad Cities. In addition, none of
the existing studies have used the PAPM theoretical framework to explain the barriers of HIV
PrEP prescription. I remarked that multiple logistic regression is commonly used in HIV PrEP
studies that I explored. However, none of the reviewed articles has used the logistic regression
on dummy variables, multiple linear regression or analysis of variance (ANOVA) as statistical
analysis tools. These gaps in the literature and methodology motive me to explore the elements
that have a bearing on PrEP prescription so that public health education efforts can be tailored to
fill the gaps. The next chapter of this dissertation proposal not only details the research
methodology but also describes the statistical procedures used to test the research hypotheses.
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Chapter 3: Research Method
Introduction
In this study, I scrutinized whether the frequency of PrEP prescription among primary
care providers and HIV specialists is associated with PrEP awareness, the number of years of
service, and provider’s types respectively. Explicitly, I explored the barriers to HIV PrEP
prescription and education needs among care providers. The setting was the great Quad Cities
area up to 70 miles radius from the city of Rock Island in Illinois. One hundred physicians
participated in the study. I used the Internet research tools to search for an updated list of primary
care providers and HIV specialists practicing in the Quad Cities for May 15, 2015 as an ample
frame. I (a) defined in deep the study population (i.e., the whole set of significant units of
analysis), (b) explained the sample design (i.e., the subset of the study population), (c)
determined the sample size (i.e., subgroup of sampling units from a research population;
Frankfort-Nachmias & Nachmias, 2008, pp.162-185), and (d) used SPSS and G*power analysis
tools for potential statistics tests. In this chapter, I discuss the research design and the
justification for its use for this study. I also discuss the target population and setting, research
parameters, estimated sample size, and the participants’ eligibility criteria. Next, I provide
information on the instrumentation, data collection, and statistical methods. Additionally, I
discuss the threats to internal, external, and constructs validity. The chapter ends with a summary
preceded by the discussion on the ethical procedures.
Design and Approach
The method of inquiry for the study was descriptive, a cross-sectional quantitative study
of barriers associated with the frequency of PrEP prescription among primary care providers, and
HIV specialists. Parameters like awareness of PrEP, the number of years spent as a prescriber in
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the medical field and the provider types were assessed. For the independent variables, the
frequency of HIV PrEP prescription was analyzed to test the following questions and
hypotheses:
Question 1: What is the association between HIV PrEP awareness and the frequency of
PrEP prescription among primary care providers and HIV specialists in the Quad-Cities?
H01: There is no association between HIV PrEP awareness and the frequency of
PrEP prescription among primary care providers and HIV specialists in the Quad-Cities.
Ha1: There is an association between HIV PrEP awareness and the frequency of PrEP
prescription among primary care providers and HIV specialists in the Quad-Cities.
Question 2: What is the association between the number of years of service as a primary
care provider or HIV specialist and the frequency of PrEP prescription among primary care
providers and HIV specialists in the Quad-Cities?
H02: There is no association between the number of years of service as a primary
care provider or HIV specialist and the frequency of PrEP prescription among primary care
providers and HIV specialists in the Quad-Cities.
Ha2: There is an association between the number of years of service as a primary care
provider or HIV specialist and the frequency of PrEP prescription among primary care providers
and HIV specialists in the Quad-Cities.
Question 3: What is the difference between provider types and the frequency of PrEP
prescription among primary care providers and HIV specialists in the Quad-Cities?
H03: There is no difference in providers’ type and the frequency of PrEP prescription
among primary care providers and HIV specialists in the Quad-Cities.
Ha3: There is a difference in provider type and the frequency of PrEP prescription
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among primary care providers and HIV specialists in the Quad-Cities.

Justification for Using This Design and Approach
The cross-sectional design allowed me to use questionnaires to collect information from a
random sample of primary care providers regarding their attitude and experience towards PrEP
prescription at one in time. Frankfort-Nachmias and Nachmias (2008) stated that cross-sectional
design is not only appropriate to describe the association between variables but also to ask
survey participants questions about their attitudes, backgrounds, and experience. In addition, the
cross-sectional design offers wide data collection tools including electronic mail and paper-based
surveys through mail questionnaires (Hall, 2008) that I used as data collection methods. Hall
(2008) acknowledged that the survey is one of the most common data collection techniques for
cross-sectional designs. A cross-sectional design is open to different data collection methods
including the Internet, face-to-face interviews, self-administrated/mailed questionnaires, and
phone interviews (Hall, 2008). Whiteside et al. (2014) applied a cross-sectional design to HIV
PrEP study in STD clinics. Despite its applicability to various studies, a cross-sectional design
has some methodological limitations. Some weaknesses of the cross-sectional design include
non-response biases associated to low response from the participants and the difficulty of
estimating the research outcome precisely with a small sample size (Barratt & Kirwan, 2009). I
addressed the weaknesses by selecting a large sample size to increase the response rate.
Methodology
Target Population and Setting
The study population included primary care providers who can prescribe in the Quad
Cities area in the United States as of May 15, 2015. The setting was health care facilities (i.e.,
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Genesis Group, Trinity Unity Care, and other medical groups’ facilities). The sampling units
included prescription drug prescribers (i.e., family practitioners, pediatricians, internists,
obstetricians/gynecologists and infectious disease/HIV specialists). The sampling frame was
based on the available updated online lists of the primary care providers operating within 70
miles radius of the City of Rock Island as of May 15, 2015. The search criteria included (a)
Sorting by the distance within 70 miles radius from the city of Rock Island and (b) specialty.
Research Parameters
The research parameters included HIV PrEP awareness, the number of years of service,
and the provider types as predictors for the frequency of PrEP prescription. The study targeted
the cities of Davenport, Bettendorf, Clinton, De Witt, Wilton, Le Claire, Muscatine, Blue Grass,
Eldridge, Orion, and Durant, Iowa City, in Iowa. I also included Rock Island, Milan, Silvis, East
Moline, Moline, Alpha, Cambridge, Fulton, Cordova, Colona, Aledo and Coal Valley, Peoria, in
Illinois. In this study, I examined five subpopulations including, family practitioners,
pediatricians, internists, obstetricians/gynecologists and infectious diseases physicians including
HIV specialists. The last sub-population served as a control stratum for comparison purpose.
The potential PrEP prescribers accounting for the five sampling subpopulations included
440 family physicians, 106 obstetricians/gynecologists, 341 internists, 124 pediatricians, and 17
infectious disease/HIV specialists. There were 963 physicians working in the area as of May 15,
2015 from which, I selected the sample population through appropriate probability sampling
methods. I projected to use the physicians’ list available at the Illinois Department of Public
Health as a supplement to the sampling frame to avoid incomplete sampling frame error.
Frankfort-Nachmias and Nachmias (2008) defined incomplete sampling frame as the missing of
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some sampling units from the list. The survey response rate is often very low among physicians
(Kellerman & Herold, 2001; Pit, VO, & Pyakurel, 2014; VanGeest, Johnson, & Welch, 2007).

Sample Size
I ran G*Power software to calculate the sample size. Power analysis allows researchers to
derive the sample size and sample size estimate for a study (Trochim, 2006a). It consists of
running the F-test (i.e., linear multiple regression fixed model with R-square deviation from
zero). I took into account the parameters for two-tailed analysis like effect size f square of 0.15,
an alpha of 0.05, and an input power of 80%, 90% or 95% as needed. The three predictors
involved in this analysis are HIV PrEP awareness, the number of years of service, and the
differences in specialties. The results for 80% power shows N of 78, N of 100 for 90% power,
and N of 119 for 95% power. I started with N= 120 (i.e., given by 95% power) plus additional
54% (i.e., plus 65 = 185 total) preliminary participants. The graphs below show the results from
the G*power F-test.
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Figure 2. Using G*Power graphs to generate the sample size.
For the confidence interval (CI) = 80%, the graph showed sample size N = 78; for a CI = 90%,
the graph showed N = 100; for a CI = 95%, the graph showed N = 120.

Since the sample size was determined, I set the 18% proportion strategy to determine the
sample size for each stratum. If a stratum has a population < 20, the entire population was taken
into account, and the 18% proportion is not applied. I summarized the breakdown of the sample
size per provider type in Table 2. Next, I verified the representativeness of the sample size based
on the size of an acceptable standard error calculation. This process is the obligatory path to
determine the accuracy of the study results. I incorporated the values of the effect size, power,
and alpha level in the analysis.
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Table 2
Breakdown of the Sample Size per Provider Type
Provider types

Number in the

Sample size selection

Projected sample size

sample frame per 70

criteria/strategy

per provider type

miles radius from the

(sample size/total

city of Rock Island

population*100)

Family practitioners

440

16.63% proportion

74

Pediatricians

124

16.63% proportion

21

Internists

341

16.63% proportion

57

Obstetricians/

106

16.63

18

17

Not applied*

17 - 2* = 15

Total

1,028

16.63% proportion

170

Actual total sample

74+21+57+18+15*

Gynecologists
Infectious
disease/HIV
specialists

= 185

size is

Note. *Proportion not applied if the total population in the stratum is less than 20.
2* is the number of the selected participants for the pilot study and excluded from the actual
study
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I requested a change in the procedure, and I was authorized by the IRB committee to
increase the number of participants from 185 to 300 to scale up the response rate close to 30%
that was found during the pilot study. I added 23 participants to each subpopulation group shown
on the preliminary breakdown of the actual study population group. The final breakdown showed
97 (74 + 23) family practitioners, 44 (21 + 23) pediatricians, 80 (57 + 23) internists, 41 (18 + 23)
obstetricians/gynecologists, and 38 (15 + 23) infectious disease/HIV specialists.

Eligibility Criteria for Participants
Participants were registered and licensed physicians who practiced in the geographical
area defined previously as of May 15, 2015. They must have belonged to an infectious diseases
specialty or any of the types of physicians that fall under primary care practice. They included
family practitioners, pediatricians, internists, obstetricians/gynecologists, and infectious
disease/HIV specialists.

Characteristics of the Selected Sample
The sample design of the study was a proportional stratified random sample with five
strata: family practitioners, pediatricians, internists, obstetricians/gynecologists, and infectious
disease/HIV specialists. The population consists then of N = N1+N2+N3+N4+N5 with N1
family doctors, N2 pediatricians, N3 internists, N4 obstetrician/gynecologists, and N5 infectious
disease/HIV specialists. Knowing the definite number in each stratum, I selected a proportional
sampling fraction of 18% from each stratum. Next, I applied the simple random sampling
procedure to each list to select the participants for the study. Overall, I began with proportionate
sampling strategies by stratifying the population into appropriate subcategories and then took a
random sample within each subcategory. The number of participants, who I recruited from each
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subcategory, was identical to their proportion in the study population (Wadsworth Cengage
Learning, 2005). However, I expanded the sample size to all individuals in the strata that
contained less than 20 people to avoid obtaining a low response from one group. I also used very
aggressive follow-up strategies including mailing reminders and in-person doctors’ office visits
to collect the completed questionnaires. I also planned, if necessary, to give a blank
questionnaire to those who might lose their early questionnaire for immediate completion during
the on-site follow-up visits.
Instrumentation
In this section, I focused on the questionnaire that I used to collect my data. I divided the
questionnaire into six fragments. The first fragment contained three questions related to the
demographic information (i.e., area zip code, gender, and age). The second part consisted of one
closed-ended question. A set of eight answers was offered to choose that most closely reflects the
level of participants’ awareness of PrEP. The third category also had one closed-ended question
on the frequency of PrEP prescription. Participants were offered a set of eight responses and
have had to choose one that most describes how often they prescribe PrEP. I built the fourth,
fifth, and sixth groups of questions on the similar model. The respondents were offered multiple
choices of answers and were asked to choose one answer that most closely describes their
opinion. The questionnaire covered the number of years of service as a primary care provider or
as HIV specialist, the difference in specialties, PrEP prescription attitudes, and barriers
respectively (Appendix A).
I used the modified Glanz et al. (2008) PAPM stage clarification algorithm to develop the
survey questions. It helped me to investigate the first null hypothesis: There is no association
between HIV PrEP awareness as an independent variable and the frequency of PrEP prescription
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as an outcome among primary care providers and HIV specialists in the Quad Cities. I
represented the modified algorithm to clarify PAPM stage in the Table 3.
Table 3
Modified PAPM stage Algorithm to Assess PrEP Awareness
Questions and answers

Corresponding PAPM
stage

1. Have you ever heard about HIV Pre-exposure Prophylaxis

Stage 1

(PrEP)?
No
Yes [go to question 3]
2. Have you ever prescribed PrEP to a client?

Stage 6

Yes
No, [go to question 3]
3. Which of the statements below describes better your opinions
about prescribing PrEP?
I have never thought about prescribing PrEP to clients

Stage 2

I am undecided about prescribing PrEP to clients

Stage 3

I am resolved to not prescribe PrEP to clients

Stage 4

I am resolved to prescribe PrEP to clients

Stage 5

Source. Adapted from “Precaution Adoption Process Model: Stage Classification Algorithm,” by K.
Glanz, B. K. Rimer, & K. Viswanath, 2008, Health Behavior and Health Education:
Theory, Research, and Practice (4th Ed.), p. 136. Copyright 2008 by John Wiley & Sons, Inc.
Note. The permission to adapt the Table is available in Appendix B.
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Glanz et al., (2008) used the algorithm to describe how Weinstein et al., (1998) applied
PAPM to their home radon testing study in Columbus, Ohio. The algorithm not only inspired me
to develop the questionnaire but also assisted me during data interpretation process. Next, I
tested the questionnaires for reliability and validity through a pilot study.
Pilot Tests
I needed a minimum of eight returned surveys (i.e., 42.11% response rate) to consider the
pilot test result as valid. To reach that goal, I started the survey with 19 physicians (i.e., 10% of
N = 185 projected for the main study) to avoid nonresponse bias. The breakdown of the 19
participants is as follow, 6 family practitioners, 3 pediatricians, 4 internists, 4
obstetricians/gynecologists, and 2 infectious disease/HIV specialists. I passed out the selfadministered questionnaire to the participants. I asked them to give me feedback in writing
format regarding items and instructions that they found unclear or difficult to understand. I
involved my Chair, my second committee member, and the Institutional Review in the pilot test
process monitoring to ensure that the process was compliant with the standards. A copy of the
questionnaire is inserted in Appendix A.
Data Collection and Analysis
I collected quantitative, categorical data including nominal and ordinal data in this
study. I gathered primary data through the self-administered paper-based survey. I used the
United States’ postal mailing system to distribute the questionnaires. I mailed the survey to185
physicians at the beginning. I needed minimum 78 of returned surveys corresponding to 80%
confidence interval to accept the results as valid. My plan to reach that goal was to increase the
sample size. For example, I started the survey with 185 participants (i.e., 120 corresponding to
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95% confidence interval increased by 54%). In addition, I included a survey monkey link in the
mail for those who might not be comfortable with mailing back the survey. A questionnaire
cover letter and a stamped return envelope were included in the mailing.
The study had one ordinal outcome (i.e., the frequency of HIV PrEP prescription). Also,
it had two nominal independent variables (i.e., HIV PrEP awareness and the difference in
provider’s type), and one ordinal independent variable (i.e., the number of year of service). I
included individuals (e.g. persons who can prescribe HIV PrEP), and groups (e.g. different
medical specialties) as the research units of analysis. In a study, the unit of analysis is who or
what about which an investigator may generalize (Long, 2013). I have planned to ask for PrEP
prescription records from the Illinois and Iowa Department of Public Health. However, I
aborted that option for confidentiality reasons.
I used SPSS statistical software to analyze data. I conducted a descriptive statistics
analysis to generate the data summary. In addition, I applied statistical analyses to test the
hypotheses. The variables that I considered in the descriptive statistics were age, gender, the
number of year of service, and the frequency of HIV PrEP prescription. The statistical analysis
section consisted of determining the suitable statistical test for each of the three research
questions.
I projected to apply the logistic regression to analyze the research question 1: What is the
association between HIV PrEP awareness and the frequency of PrEP prescription among primary
care providers and HIV specialists in the Quad Cities? The eight levels associated with the
independent variable (HIV PrEP awareness) included very much, much, quite a bite, a little, very
little, none, don’t know and no answer (Appendix A). I grouped these parameters in a
dichotomous variable coded as unaware for the responses that fall under very little, none, don’t
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know and no answer and aware for the responses that fall under very much, much, quite a bite, a
little. For the research question 2: What is the association between the number of years of service
and the frequency of PrEP prescription among primary care providers and HIV specialists in the
Quad Cities, I planned to use logistic regression analysis too. It offered the opportunity to group
the predictor years of service into binary variables coded as fewer years of experience for
physicians who have less than five years of experience and more years’ experience for those who
have more than five years of experience in medical field.
I projected to apply the ANOVA to the research question 3: What is the difference
between provider type (i.e., family practitioners, pediatricians, internists,
obstetricians/gynecologists, and infectious disease/HIV specialists) and the frequency of PrEP
prescription among primary care providers and HIV specialists in the Quad Cities? In a study,
the investigators use ANOVA when they want to determine whether specific groups have unlike
effects (Barnes, & Writer, 2012). More specifically, ANOVA was suitable to determine whether
belonging to each of the groups (i.e., family practitioners, pediatricians, internists,
obstetricians/gynecologists, and infectious disease/HIV specialists) means higher or low HIV
PrEP prescription frequency.
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Table 4
Statistical Analysis Plan and Results Reporting Strategy of the Research Variables
Variables that I intended to collect

Source

Nature

Frequency of HIV PrEP

Cross- Sectional Survey of

Continuous/Categorical (Ordinal)

prescription

Physicians

Review of archived medical
reports available at the local or
State Department of Public Health
HIV PrEP awareness

Cross- Sectional

Categorical (Nominal)

Survey of Physicians
Number of year of service:

Cross- Sectional

Zero to five years

Survey of Physicians

Categorical (Ordinal)

Five to ten years
10 to 15 years
15 to 20 years
20 years and more
Difference in provider type

Cross- Sectional
Survey of Physicians

Family practitioners
Internet-based search and
Pediatricians

official list of physicians available at
local public Health Department

Internists
Obstetricians/Gynecologists
Infectious Disease/HIV specialists

Categorical (Nominal)
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Statistical Methods
After the survey data have been collected, I entered them into Excel database. I created
an SPSS data file to run multiple logistic regression analysis. SPSS allowed me to investigate
the association between the independent variables (i.e., PrEP awareness level and the number
of years spent as a prescriber in the medical field). It was a useful tool to test the null
hypotheses one and two (i.e., 1. There is no association between HIV PrEP awareness and the
frequency of PrEP prescription among primary care providers in the Quad Cities; and 2. There
is no association between the number of years of service and the frequency of PrEP
prescription among primary care providers in the Quad Cities). For each variable of interest, I
projected not only to calculate unadjusted odds ratios and 95% confidence intervals for in
across-group comparisons purpose, but also I planned to include a p-value < 0.05 in the
multivariate model. I also looked at a combined model to determine whether all three
independent variables predict PrEP prescription.
I projected the logistic regression test for the research question1: What is the association
between HIV PrEP awareness and the frequency of PrEP prescription among primary care
providers and HIV specialists in the Quad Cities? The analysis consisted of collecting data by
using eight levels break down of the independent variable or predictor (i.e., awareness levels:
Very much, much, quite a bit, a little, very little, none, don’t know, and no answer). I collected
data on multiple levels independent variables or predictors and one outcome variable (Green &
Salkin, 2011). There is one independent variable (X = HIV PrEP Awareness with eight
dummies) and one outcome (Y = Frequency of HIV PrEP prescription). Since I used nonexperimental methods, it is appropriate to call X and Y respectively as a predictor and the
criterion (Green & Salkin, 2011). This test is important to examine whether I can use HIV
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PrEP awareness score to predict the frequency of HIV PrEP prescription among primary care
providers and HIV specialists respectively.
I also planned to use the logistic regression to analyze the research question 2: What is
the association between the number of year of service and PrEP prescription frequency among
primary care providers and HIV specialists in the Quad Cities? In this question, the variable
year of service was divided into five groups. I coded the groups in dichotomous variables,
fewer years of experience and more years of experience. I represented the groups in the
following format, 0 to 5 years of service for those fall under fewer years of experience in
medical field and the remaining, 5 to 10 years of service, 10 to 15 years of service, 16 to 20
years of service, and 21 years and more fall under more years of experience in medical field.
First, I checked for the assumptions of logistic regression. An assumption is a condition
that allows a researcher to aware of the effectiveness of what he or she attempts to do. In a
study, the assumptions must be met to avoid statistical analysis biases (Field, 2012). The first
assumption was whether the variable follow the normal distribution. The second assumption
included additivity and linearity. For example, the dependent variable and dummy variables
will not be estimated accurately when non-linear interactions occur in the terms of relationship
(Osborne & Waters, 2002). Consequently, the true associations will be underestimated, and
cause Type I and Type II errors. Therefore, it was important to examine the residual plots to
detect an eventual nonlinearity (Osborne & Waters, 2002). The third assumption was the
reliability of the variables’ measurement (i.e., there is no measurement error). The fourth
assumption was about the homoscedasticity or homogeneity of variance (i.e., one has the same
variance of errors through all levels of the independent variable, Osborne & Waters, 2002).
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I planned to apply the ANOVA to Question 3: What is the difference between provider
type (family practitioners, pediatricians, internists, obstetricians/gynecologists and infectious
disease/HIV specialists) and the frequency of PrEP prescription among primary care providers
and HIV specialists in the Quad Cities? The five dummy variables that fall under the predictor
(i.e., provider type) include
1. Family Practitioners (X1)
2. Pediatricians (X2)
3. Internists (X3)
4. Obstetricians/Gynecologists (X4), and
5.

Infectious Disease/HIV specialists (X5).

I run the ANOVA F test to evaluate the magnitude of the difference between the group
means on the frequency of PrEP prescription from each other group. I checked for the
following assumptions: Normal distribution of the dependent variable for each dummy
variable, same variances of the dependent variable for all dummy variables, and the
independence of the cases and the scores on the test variable. The violation of the independence
assumption could cause ANOVA F test to yield inaccurate p-values (Green, & Salkind, 2011).
Later, I projected to run a post hoc test (Tukey’s HSD) to determine which specific groups
differ.
Since the outcome (i.e., the frequency of HIV PrEP prescription) is an ordinal variable
that is associated with the three independent variables, I can use the nonparametric tests to
analyze the research hypotheses. Field (2013) stated that researchers use the nonparametric
tests for ordinal data in a study where fewer assumptions were made. He précised that the
nonparametric tests do not assume specific distribution instead use the histogram as data
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interpretation tool. In another hand, the parametric statistic tests involved interval and ratio data
with normally predictable distribution (Field, 2013).
The two nonparametric tests that could be applied to this study are Wald-Wolfowitz
runs and Mann-Whitney tests. Wald-Wolfowitz runs are suitable for the first hypothesis: There
is no association between HIV PrEP awareness and the frequency of PrEP prescription among
primary care providers and HIV specialists in the Quad Cities. It was convenient to look for
runs of scores from each of the primary providers and HIV specialists’ group within the ranked
order (Field, 2013) respectively.
I planned to use Mann-Whitney tests for the second null hypothesis: There is no
association between the number of years of service as a primary care provider and the
frequency of PrEP prescription among primary care providers and HIV specialists in the Quad
Cities. This test was appropriate when researchers want to look at, in the “differences in the
ranked position of scores in different groups” (Field, 2013)
Mann-Whitney tests model could also be applied to analyze the third null hypothesis,
H0: There is no difference in family practitioners, pediatricians, internists,
obstetricians/gynecologists and infectious disease/HIV specialists and PrEP prescribing habits
among primary care providers and HIV specialists in the Quad Cities. I run the different tests
mentioned. The trustfulness and the confidence of the research results depended on the
inquirer’s ability to control and evaluate potential threats to validity (Gast &Ledford, 2014). I
presented the statistical analysis plan on Table 5 and the summary of the statistical analysis and
justifications on Table 6 respectively.
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Table 5
Statistical Analysis Plan and Results Reporting Strategy
Statistical

Research

analysis steps

Nature of the questions

Statistical tests

Results

questions and

by using SPSS

reporting

variables

software

strategies

Demographic

Expressed as

Descriptive

Tables and, or

Format

information

percentages,

analysis

graphs

research

(i.e., age,

proportion, ratios,

(Note: Tables

variables (i.e.,

gender,

modal values or as

will contain

describe

number of year

central tendency,

the frequency

demographic

of service and

variability and shape

and

information,

geographical

percentage of

frequency

situation:

the

distributions

Illinois vs.

categories)

and missing

Iowa; and the

values

frequency of
HIV PrEP
prescription)

(Table continues)
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Statistical

Research

analysis steps

Nature of the questions

Statistical tests

Results

questions and

by using SPSS

reporting

variables

software

strategies

Group &

Question 1:

Relate more than 2

Logistic

Tables and,

categorize data

What

variables coupled with

regression

or, figures

(i.e., use

is the

group comparison

computer to

association

within 1 independent

place data in

between HIV

variable with dummy

category of the

PrEP

(8 levels break

research

awareness

down of PrEP

variable)

and the

awareness

frequency of

(i.e.,Very much, much,

PrEP

quite a bit, a little, very

prescription

little, none, don’t know

among primary

and no answer) and 1

care providers

dependent variable (the

and HIV

frequency of PrEP

specialists in

prescription). It

the Quad-

expresses the degree of

Cities?

the relationship.

(Table continues)
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Statistical

Research

analysis steps

Nature of the questions

Statistical tests

Results

questions and

by using SPSS

reporting

variables

software

strategies

Create and label

Question 2:

The question relates 5

Logistic

Tables and, or,

table to report

What is the

combinations of the

regression

figures

the results

association

predictor, years of service

appropriately

between the

(i.e., Zero to five years,

number of years

five to ten years, ten to 15

of service as a

years, 15 to 20 years and

primary care

20 years and more) to one

provider or HIV

dependent variable (the

specialists and

frequency of PrEP

the frequency of

prescription). It expresses

PrEP

relationship/prediction.

prescription
among primary
care providers
and HIV
specialists in
the Quad-Cities?

(Table continues)
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Statistical

Research

analysis steps

Nature of the questions

Statistical tests

Results

questions and

by using SPSS

reporting

variables

software

strategies

Question 3:

It relates five categories One-way

Tables and,

What is the

(i.e., Family

ANOVA

or, figures

difference

Practitioners,

&

between

Pediatricians,

Post Hoc test

provider types

Internists,

and the

Obstetricians/Gynecolo

frequency of

gists and infectious

PrEP

diseases physicians

prescription

including HIV

among primary

specialists) of

care providers

independent variable

and HIV

(provider type) with

specialists in

one quantitative

the Quad-

dependent variable (the

Cities?

frequency of PrEP
prescription). It
expresses group
differences.
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Table 6
Summary of the Statistical Analysis and Justifications
Research Questions

Projected Statistical Analysis

Justifications

Research Question 1:

Logistic Regression

The research question involves a

What is the association

binary (dichotomous) DV and

between HIV PrEP

Researchers performed this analysis

dichotomous independent

awareness and the

on a binary dependent variable (DV) variables.

frequency of

and binary independent variables

Code for DV:

PrEP prescription

(IV).

Low frequency = 0;

among primary care

It presents many advantages

High frequency = 1

providers and HIV

including (a) help to predict on DV

Code for IV:

specialists in the Quad-

from the ID data; (b) it is easier to

Unaware = 0;

Cities?

calculate and interpret the odds ratio

Aware = 1

for a better understanding of the

Logistic regression analysis is a

predictors.

stable and powerful model. Not
only it helps researchers to
represent intervals or levels but
also increases the probability of
events.

Research Question 2:
What is the association

(Table continue)

Logistic Regression

The research question involves a
binary DV and dichotomous
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Research Questions

Projected Statistical Analysis

Justifications

between the number of

Researchers performed this analysis

independent variables.

years of service as a

on a dichotomous dependent

primary care provider

variable (DV) and dichotomous

Code for DV:

or HIV specialists and

independent variables (IV)

Low frequency = 0;

the frequency of PrEP

High frequency = 1

prescription among
primary care providers

Code for IV:

and HIV specialists in

less (< 5) = 0; more (> 5) = 1

the Quad-Cities?
Research Question 3:

Analysis Of Variance (ANOVA)

The question involves five groups

What is the difference

Post hoc test

(i.e., family practitioners,

between provider types

pediatricians, internists,

and the frequency of

Researchers used ANOVA when

obstetricians/gynecologists and

PrEP prescription

they deal with more than two

infectious disease/HIV specialists).

among primary care

groups.

There are more than two means to

providers and HIV

compare. Using multiple t-tests

specialists in the Quad-

might be too complicated. I use

Cities?

ANOVA to avoid conducting
multiple t-tests. Also, ANOVA
will allow me to gather all the data
into one number (F).
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Threats to Validity
The extent to which a researcher measures, what he or she plans to measure effectively, is
referred to as “validity” (Frankfort-Nachmias & Nachmias, 2008). Frankfort-Nachmias and
Nachmias also mentioned that it is crucial, in quantitative inquiry, to provide steady evidence to
support whether the variable measuring tools that one uses are reliable. It is also important to
control and evaluate the study’s internal, external and construct validity threats (Creswell 2009;
Frankfort-Nachmias & Nachmias, 2008; Gast &Ledford, 2014).
Internal validity is about the causal effect attribution of the dependent variable on the
independent variable (Frankfort-Nachmias & Nachmias, 2008). The threats to internal validity
include any factor that can trigger researchers’ ability to make sound inferences from the
research data (Creswell, 2009). Some of the internal validity threats can arise from participants’
selection methods, history, compensatory rivalry, testing, and instrumentation (Creswell, 2009). I
limited the internal validity threats by selecting participants randomly and by reducing
expectations of the HIV specialists versus primary care providers. It is also important to create
equality between different subgroups involved in a quantitative study and to use the same
instrument for each sub-group (Creswell, 2009). Researchers were also concerned about the
effect of the variable on “other natural settings and on the large populations” (FrankfortNachmias & Nachmias, 2008) to ensure the study’s external validity.
External validity stressed on the generalizability of research to the large population (Gast
&Ledford, 2014). External validity threats can occur through improper inferences process that
links data to participants, different settings and situations (Creswell, 2009). The external validity
threats may include various interactions between (a) selection and treatment, (b) setting and
treatment, and (c) history and treatment (Creswell 2009). I addressed the threats by restricting
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claims among the subpopulation in which the generalization of the study results is limited and by
engaging participants from different settings in the study (Creswell, 2009). In addition, I planned
to replicate the same research to compare the results to the actual study in future. It is also
indispensable to evaluate the compliance of the data collection instrument to “the concepts and
the theoretical assumption” (Frankfort-Nachmias & Nachmias, 2008) of the study by controlling
the threats to construct validity.
Construct validity allows researchers to prove the alignment of the study instruments to
the theoretical framework (Frankfort-Nachmias & Nachmias, 2008). For instance, FrankfortNachmias and Nachmias cited Miltron Rokeach (1960) who developed a dogmatism
questionnaire to assess the association between close-mindedness and ideological orientations. It
is capital to establish convergent and discriminant validity of the study. Convergent validity
consists of illustrating that the measures that were expected to be related were related effectively.
Discriminant validity ensures that the measures that were expected to be different were not tied
one to another as expected (Trochim, 2006c).
Ethical Procedures
Researchers’ primary responsibilities are to be obedient to ethical standards and to
behave properly as far as the research involves human beings (Rudestam & Newton, 2007). This
study was strictly anonymous and confidential. For example, while sending e-mails, I protected
participants’ addresses by using Blind Carbon Copy. I also reminded participants to not put their
returning address on the envelop containing their feedback letter. I included the invitation to
participate in research letter coupled with implied consent statement, Wiley Global permissions
to adapt PAPM algorithm for Figures 1 and Table 2 in Appendix B and Appendix C respectively,
and the pilot test questionnaire in Appendix A for the IRB application.
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I addressed potential ethical issues regarding the study process and recruitment materials
by alerting my Chair as the issues arise. I was also obedient to the Walden University’s research
ethical standards. I had exclusive access to the data, which I stored in a secured location. For
example, the printable documents were kept in a locked cabinet. I also used a password protected
computer and back up on the password protected jump-drive. Data would be deleted according to
the timeframe allowed by the school standards. Finally, I disclosed any conflict of interest (i.e.,
dissertation study grants, the work environment) and justified the use of any incentives to
encourage participants (if it is applied) to ensure a better turnout of the survey.

Summary
In this chapter, I provided general information about the methodology of the study. The
information was about the research design, the target population, the setting, research
parameters, sample size, eligibility criteria, and instrumentation. I not only discussed the
approaches to the analysis of the research variables but also discussed the statistical methods to
test the research questions and hypotheses. Multiple logic regression analysis and Nonparametric statistics test if necessary were projected to be used to assess the extent of the
association between independent variables and the outcome variable of interest. I further
discussed the potential internal, external, and the constructs validity threats to the study. The
chapter ended with an overview of the ethical procedures. In Chapters 4 and 5, I analyze the data
collection process through the cross-sectional survey among primary care providers and HIV
specialists, and discuss the findings of the study respectively.
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Chapter 4: Results
Introduction
In this study, I aimed to understand the barriers to prescribing HIV PrEP among primary
care providers and HIV specialists using the independent variables of PrEP awareness, the
number of years of service, and provider’s types. I also included gender, and geographic
situation. These sociodemographic variables may predict the frequency of PrEP prescription
(outcome variable) among primary care providers and HIV specialists. I described the research
questions and hypotheses as follows:
Research Question 1: What is the association between HIV PrEP awareness and the
frequency of PrEP prescription among primary care providers and HIV specialists in the QuadCities?
Ho1: There is no association between HIV PrEP awareness and the frequency of
PrEP prescription among primary care providers and HIV specialists in the Quad-Cities.
Ha1: There is an association between HIV PrEP awareness and the frequency of PrEP
prescription among primary care providers and HIV specialists in the Quad-Cities.
Research Question 2: What is the association between the number of years of service as a
primary care provider or HIV specialist and the frequency of PrEP prescription among primary
care providers and HIV specialists in the Quad-Cities?
Ho2: There is no association between the numbers of years of service as a primary
care provider and the frequency of PrEP prescription among primary care providers and HIV
specialists in the Quad-Cities.
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Ha2: There is an association between the numbers of years of service as a primary care
provider and the frequency of PrEP prescription among primary care providers and HIV
specialists in the Quad-Cities.
Research Question 3: What is the difference between provider types and the frequency of
PrEP prescription among primary care providers and HIV specialists in the Quad-Cities?
Ho3: There is no difference in provider types and the frequency of PrEP prescription
among primary care providers and HIV specialists in the Quad-Cities.
Ha3: There is a difference in provider types and the frequency of PrEP prescription
among primary care providers and HIV specialists in the Quad-Cities.
The results of the pilot study and their impacts on the main study are reported in the
chapter. The results and findings of the actual study are reported in narrative, tabular and figure
formats. The chapter ends with a descriptive summary of the study interpretation and outcomes.
Pilot Study
The pilot study covered 53 days (see Figure 1 for the timeline), and targeted 30
Physicians in the following specialties: seven family practitioners, four infectious disease/HIV
specialists, seven internists, six obstetricians/gynecologists, and six pediatricians. There were 15
females and 15 males randomly selected. Geographically, the participants were equally
distributed, 15 participants in the Quad-Cities Illinois and 15 participants in Quad-Cities Iowa.
This pilot test aimed to ask physicians to read and complete the questionnaire and give me
feedback regarding items and instructions that they found unclear to understand.
The participants answered to the following feedback questions after they had completed the
survey:
1. How long did it take you to complete this survey?
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2. What is your interest in HIV PrEP issues?
3. What is your understanding of the survey questions?
4. Is the sequence of the questions encouraged or discouraged your desire to continue
with the survey?
5. Have you hesitated to answer any questions because you need clarification on some
points?
6. Was there anything objectionable in the survey?
7. Is there anything in the survey that is not relevant or appropriate for your culture?
8. Please, write down any wording that would have been clearer on the lines bellow.
There were nine respondents out of 30 potential participants corresponding to a 30% response
rate. Over 77% (7 out of 9) respondents said that they had a greater interest in HIV PrEP issues,
whereas 11.11% had an interest in PrEP issues. More than 66% of the respondents had a good
understanding of the survey, and 22.22% had a fair understanding. More than 88% of the
respondents (i.e., 8 out of 9 people) said that the sequence of questions had encouraged them to
continue with the survey. All of the respondents (100%) did not hesitate answer, find anything
objectionable or needed clarification on any wording remarks in the data collection instrument.
The feedback and comments from the participants showed the following:
Survey Duration
It took a minimum of 1 minute and a maximum of 5 minutes to complete the survey. The
average time was 2 minutes and 30 seconds. I projected 2 to 5 minutes to complete the
questionnaire for the main study.
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Interest in PrEP Issues
Up to 66.67% of the respondents had a greater interest in the PrEP issues, 11.11% had an
ordinary interest, and 11.11% had little interest.

Understanding of the Questions
Up to 77.78% of respondents had a good understanding of the questions, 22.22% had a fair
understanding, and 0% had a poor understanding.

Sequence of Questions
About 89% of respondents said that the sequence of the questions encouraged them to continue
the survey. The answers were No for each of the following Yes or No questions regarding (a)
participants’ hesitation to answer, (b) points that need clarifications, (c) anything objectionable,
(d) anything not relevant/appropriate, and (e) any wording. The spaces provided for the
comments and remarks were left blank. I presented the results on Table 7. I also reported the
timeline of the pilot study on Figure 3 and the summary of the pilot test and its inferences on
Table 8 respectively.
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Figure 3. Pilot study timeline.
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Table 7
Data Report Showing Participants’ Responses (n = 9)
1)

How much do you known about HIV Pre-Exposure Prophylaxis
(PrEP)?

Very

Much

Quite a

much

A little

Very little

None

bit

0

1

2

3

Don’t

No

know

answer

0

3

0

0

Very little

None

Don’t

No

know

answer

0

0

2) How often do you prescribe HIV PrEP?
Very

Often

Quite a

often

0

A little

bit

1

0

0

8

3) How long have you been served as a Physician?
0 to 5

6 to 10

11 to 15

years

years

years

0

3

1

(Table continues)

16 to 20 years

21 to 25 years

26 years and
more

3

1

1
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4) What is/are your specialty (ies)?

Family Practice

Infectious

Internist

Ob/Gyn

Pediatrician

Other

1

2

2

0

diseases
2

2

5. A- Which of the following best describes your thoughts about prescribing PrEP?

(a) I have never thought about prescribing PrEP to my

7 answers (77.78%)

clients
(b) I am undecided about prescribing PrEP to my clients

1 answer (11.11%)

(c) I have decided; I do not want to prescribe PrEP to my

0

clients
(d) I have decided; I do want to prescribe PrEP to my clients

5. B-

1 answer (11.11%)

What is the most accurate reason you may not prescribe or propose PrEP services to

your clients who might need them?
(a) I have never been in a situation that required me to prescribe or

4 answers (44.44%)

propose HIV PrEP services to a client.
(b) I don’t know much about PrEP and its guidelines/protocol to

1 answer (11.11%)

prescribe or propose its services to my clients.
(c) I think that only HIV specialists can prescribe HIV PrEP

(Table continues)

0
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(d) I think that only HIV specialists can prescribe HIV PrEP

0

(e) Insurance companies don’t want to cover HIV PrEP for my

0

Clients
(f) Clients and or I have concerns about the HIV PrEP drugs’ side
0
effects
(g) My clients cannot afford HIV PrEP services because of the high
0
cost
4

answers

(h) I have no reason
(44.44%)
6.What is the age group range that do you belong to?

18 to 24

25 to 34

35 to 44

45 to 54

55 to 64

65 to 74

75 or older

0

0

3

5 (55.56%)

1 (11.11%)

0

0

(33.33%)

7.What is your gender at birth?
Female

Male

3 (33.33%)

6 (66.67%)

8. In what zip code is your home located at?

Illinois
5(55.56%)

Iowa
3 (33.3%)
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Table 8
Pilot Test Summary and Inferences (n = 9)

Completed surveys

Actual Numbers

Percentage

9 out of 30

30%

Remarks
I will expect about 30% response
rate for the actual study

Returned to Sender because

6 out of 30

20%

I will expect about 20% of the

the participants were no

surveys sent out to be returned to

longer at the provided address

me for the actual study because the

or retired

participants might no longer at the
provided address

Some participants that did not

15

50%

respond

I will expect about 50% of the
participants that receive the survey
effectively, will not fill and send it
back to me during the actual study
data collection process.

Females responded

3 out of 15

20%

I will expect more males to respond

Males Responded

6 out of 15

40%

to the survey than females.
Statistically, about 2/3 of the
respondents will be male.

Responses from Illinois

5 out of 15

33.33%

No zip code on one

Responses from Iowa

3 out of 15

20%

Completed survey
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Results of the Pilot Study
I presented the summary and inferences of the pilot study on Table 7. The returned
responses exceeded the minimum number of height responses that was needed to consider the
pilot study valid. The respondents did not suggest any corrections to the data collection
instrument. However, there were several issues that I faced during the pilot study:


Difficulty finding the participants’ emails addresses to send them the Survey Monkey
directly. Consequently, none of the respondents sent their responses via the Internet



Difficulty locating some physicians’ offices to hand out the questionnaires



Some participants have retired or moved to other locations outside the geographic study
area



Delay in time to return the completed surveys



Low response during the first month of the data collection.

I requested a change in the data collection procedures to overcome the problems.
The Institutional Review Board (IRB) allowed me to raise the number of the surveyed physicians
from 19 to 30. IRB authorized me also to hand out the survey to the participants at their office
via their receptionists to improve the response rate of the pilot study. Therefore, I resumed the
pilot study data collection through an in-person distribution of the survey to eleven (11)
additional physicians. IRB also authorized me to make a change to the sample population for the
actual study. I increased it from 185 to 300 participants. I also use my car GPS system for
direction purpose. Finally, the pilot study allowed me to make the following projections on the
possible outcomes of the actual study:
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1. I expected about 30% response rate for the actual study
2. I expected about 20% of the surveys sent out to be returned to sender because the
participants might no longer be at the provided address
4. I expected about 50% of the participants who receive the survey, not fill it out and send
it back to me during the main study data collection process.
5. There will be more males to respond to the survey than females. Statistically, about 2/3 of
the respondents were expected to be males.

One recommendation for self-improvement regarding the data collection of the main study was
to find the ways to have the email addresses of the participants to facilitate the Internet-based
survey participation. Unfortunately, it did not work out because I must buy the email addresses
buy from a third party, which may violate the participants’ privacy and the research ethical rules.
Data Collection of the Main Study
I collected the data between October 24th, 2015 and January 24th, 2016 (i.e., 90 days).
Three hundred surveys were mailed via US postal services. I also used In-person distribution
approach to drop off the questionnaire at the Physicians’ offices. Ninety-seven family
practitioners, 44 pediatricians, 80 internists, 41 obstetricians/gynecologists, and 38 Infectious
disease/HIV specialists were surveyed. One hundred responses were returned. The response rate
was 33.33% that was slightly greater than the 30% response rate of the pilot study.
From the plan presented in Chapter 3, I noted four inconsistencies in data collection and
analysis. The first inconsistency was the change in the procedures that I have requested during
the pilot study to address low response issues that arose. For example, the IRB allowed me to
increase the number of the participants from 19 to 30 for the pilot study, and from 185 to 300 for
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the main study. I calculated the actual sample size using Raosoft sample size calculator. I chose
30% as the percentage of the response distribution based on the 30% response rate projection of
the pilot study. With 5% margin of error, 80% confidence level, and 1139 population size, the
recommended sample size was n = 124 (Raosoft, n. d.). Also based on the pilot study response
rate of 30%, it was estimated that about 450 physicians would need to be contacted to obtain at
least 144 responses. However, due to time and cost restraints the decision was made to survey
300 physicians in the hope that a 50% response rate (higher than the pilot study response rate)
could be obtained through follow-up with the potential participants. The study ended up with
33.33% response rate, resulting in a sample size of n = 100.
The IRB authorized me to use the in-person distribution approach to distribute the survey
in some physicians’ offices via their receptionists. I used a car GPS system to locate the
physicians’ offices. I prolonged the data collection period from two months to three, allowing me
to collect more survey responses to scale up the response rate above the 30%. Two issues
affected the response rate: a failure to send out the survey to the estimated 450 physicians and
lack of participants’ email to encourage online participation through Survey Monkey.
The second discrepancy was that no participant had used the Survey Monkey link provided in the
invitation letter as planned. The third discrepancy was that I dropped the binary logistic for
which the sample did not obey the normality assumption and used Kendall’s tau-b correlation
test for the analysis of the research questions one and two. The final discrepancy was the usage
of Fisher’s exact test (R x C) to analyze research question three instead of the ANOVA
announced in Chapter 3. The change was necessary because the dependent variable (i.e., the
frequency of PrEP prescription was a categorical that I changed into binary (high/low). It is not a
continious variable. Therefore, ANOVA was no longer the correct test for the research question
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3. Since I have two categorical variables, either chi-square (2x2) or Fisher’s exact test (R x C) is
the appropriate test. Furthermore, I have more than two groups in the specialty category. I also
observed low cell counts in the data. Therefore, Fisher’s exact test is the most suitable statistical
test.
Study Sample
The survey sample included 300 Physicians or 26% from the 1,139 total physician
population in the Quad Cities area and distributed across five specialties. The participants were
evenly distributed across gender (150 females and 150 males) and geographic (150 participants
from Illinois and 150 from Iowa). The final sample size was n = 100 or 8.7% of the total sample
population, corresponding to the number of participants who completed the survey. I presented
the distribution of the participants on Table 9.
Table 9
Response Rate Distribution Across Specialties (n =100)
Subpopulations

Survey sample

Actual number of responses (n)

Response rate

Family practitioners

97

30

30.93%

Infectious disease /HIV

38

11

28.95%

Internists

80

17

21.25%

Obstetricians/

41

18

43.90%

Pediatricians

44

19

43.18%

Total

300

100

33.33%

Male

150

53

35.33%

Female

150

47

31.33%

specialists

gynecologists
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Descriptive Analyses
I used the IBM SPSS Statistics 21 for all statistical analysis. The key variables were
coded and typed in the SPSS system. I conducted a series of descriptive statistics analyses. The
first analysis was a frequency test for the respondents’ gender, geographic distribution, age (by
category), years of experience (by category), and their specialty. There were N = 100 valid
responses and zero missing data.
I evaluated the zip code of respondents to determine their geographic location (i.e.,
Illinois versus Iowa). The five digits of the zip code of the Quad Cities Illinois start with 6, and
that of the Quad Cities Iowa with 5. Table 4 reveals that slightly more participants lived in Iowa.
The majority of participants were male. Many were 45 to 54 years old. The greatest number of
them had 11 to 15 years of experience. Family Practitioners were more represented. The
frequency distributions were presented on Table 10.
Table 10
Frequency distribution of demographic variables (n = 100)

Variables

Frequency

Percent

Gender of respondent
Male

53

53%

Female

47

47%

13

13%

21

21%

Age range of respondent
25-34
35-44
(Table continues)
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Frequency

Percent

31

31%

28

28%

7

7%

Illinois

48

48%

Iowa

52

52%

14

14%

16

16%

20

20%

14

14%

18

18%

18

18%

Family practitioners

30

30%

Infectious disease /HIV specialists

11

11%

Internists

17

17%

Obstetricians/gynecologists

19

19%

Pediatricians

17

17%

Variables
45-54
55-64
65-74

Location of respondent

Year of experience of respondent
0-5 years
6-10 years
11-15 years
16-20 years
21-25 years
26 and more years
Specialty
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The demographic characteristics of participants were represented on figures 4 – 8.

Figure 4. Distribution of participants across gender.

Figure 5. Geographic distribution of participants.
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Figure 6. Age range distribution of participants.

Figure 7. Distribution of participants across years of experience.
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Figure 8. Distribution of participants across specialty.

Information on other survey responses was summarized in Table 5. The majority of
respondents had very little awareness of PrEP. In addition, a higher number of them had never
prescribed PrEP or thought about prescribing PrEP to their clients either. Furthermore, many
participants declared that they don't know much about PrEP and its guidelines/protocol to
prescribe or propose its services. See results on Table 11.
Note. I redefined the dependent variable, the frequency of PrEP prescription as Prescription of
PrEP, and split it into a binary, Not prescribe PrEP coded 1 and Prescribe PrEP coded 0.
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Table 11
Frequency and Percent of Survey Responses (n=100)

How much do you know about PrEP?
Response

Frequency

Percent (%)

Very much

2

2%

Much

1

1%

Quite a bite

10

10%

A little

32

32%

Very little

36

36%

None

18

18%

Don't know

1

1%

3

3%

7

7%

89

89%

1

1%

How often do you prescribe HIV PrEP?

A little

Very little

None

No answer

Which of the following best describes your thoughts about prescribing PrEP? (Please circle one)

(Table continues)
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Response

I have never thought about

Frequency

Percent (%)

59

59%

23

23%

3

3%

13

13%

2

2%

prescribing PrEP to my clients

I am undecided about
prescribing PrEP to my clients

I have decided; I do not want
to prescribe PrEP to my clients

I have decided; I do want to
prescribe PrEP to my clients

Other opinions

What is the most accurate reason you may not prescribe or propose PrEP services to your clients
who might need them? (Please check one)
I have never been in a situation
that required me to prescribe
or propose PrEP services to a
client

(Table continues)

34

34%

80

Response

I don't know much about PrEP

Frequency

Percent (%)

53

53%

2

2%

1

1%

1

1%

9

9%

and its guidelines/protocol to
prescribe or propose its
services to my clients

I think that only HIV
specialists can prescribe HIV
PrEP

Insurance companies don't
want to cover HIV PrEP for
my client

My clients cannot afford HIV
PrEP services because of the
high cost

No reason
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I also presented these results in the pie chart format in figure 10.

Figure 9. Level of PrEP awareness among participants.

Next, to be consistent with the research method that I proposed in chapter 3, I
reset the response data for the questions regarding awareness and prescription of PrEP
into binary variables. The two components of the independent variable, awareness about
PrEP, were low awareness coded 1 and high awareness coded 2. I defined low awareness
as all answers that fall under (a little, very little, none, and don’t know). The high
awareness accounted for the answers that fall under (very much, much and quite a bit).
The two components of the dependent variable, Prescription of PrEP were, not prescribe
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PrEP coded no, and Prescribe PrEP coded yes. I considered the answers that fall under
(none, and don’t know) for not prescribe PrEP. The answers that fall under very often,
often, quite a bit, a little, and very little were categorized as prescribe PrEP. The
frequency test was run for the two binary categorical variables.
The results were presented in the pie chart formats on Figures 10 and 11
Low Awareness Versus High Awareness About PrEP

Figure 10. Dichotomous distribution of the level of awareness about PrEP.
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Eighty-seven percent of the respondents had low awareness about PrEP against 13% who
had a higher awareness about PrEP.

Prescribe Versus Not Prescribe PrEP
Only 10% of respondents had prescribed PrEP against 90% who did not prescribe it. See
results in Figure 11.

Figure 11. Dichotomous distribution of the frequency of PrEP prescription.
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Cross Tabulation Test to Compare the Frequency of PrEP Across Independent
Variables
I run a series of cross-tabulation analyses to compare the mean of the frequency of
PrEP across provider types (specialties). Fisher’s exact tests were performed for all the
other independent variables including awareness about PrEP, years of experience, and the
covariates, gender and geographic locations (Illinois vs. Iowa) because I had cell counts
that are less than 5 (Observed Values, n. d.). The results were presented in the Tables 12.
Table 12
Cross Tabulation Test of PrEP Prescription, Variables and Covariates (n=100)
Independent variables

Count for Prescribe versus Not
prescribe PrEP
Prescribe PrEP
Not
prescribe
PrEP

.181

Specialty
Family Practitioner
Pediatrician

P-Values for each
Variable

3

30

1

16

Obstetrician/Gynecologist

3

13

Infectious diseases/HIV
specialist

6

13
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Awareness
Low awareness
High awareness

.017
9

78

5

8

Years of experience
.002
0-5

6-10
11-15
16-20
21-25
26 and more

0

14

2

14

0

20

2

12

2

16

8

10

Gender
Male
Female

.361
9

44

5

42

Geographic location
Illinois
Iowa

.460
8

40

6

46
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Two-sided Fisher's exact test revealed that the differences in the frequency of
PrEP prescription across physicians’ specialties were not statistically significant. The
differences occurred more frequently than expected by chance (P > 0.05, Fisher’s exact
test). Inversely, there was statistically significant association between years of experience
and the frequency of PrEP prescription (P = .002, two-sided Fisher's exact test). Pearson
chi-square (χ2) test showed a significant association between awareness of PrEP and the
frequency of PrEP prescription (p = .017). That between years of experience and the
frequency of PrEP prescription was statistically significant too, confirming the result of
Fisher’s exact test performed earlier. Gender difference and geographic location
covariates were not associated with the frequency of PrEP prescription. The results of the
frequency of PrEP prescription across other covariates were presented in the Figures 12 –
17.

Figure 12. Frequency of PrEP across geographic locations (Illinois versus Iowa).
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Figure 13. Frequency of PrEP across age ranges of the participants.

Figure 14. Frequency of PrEP by years of experience
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Figure 15. Frequency of PrEP prescription across gender (male versus female).

Figure 16. Frequency of PrEP by the level of PrEP awareness (low versus high
awareness).
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Results by Research Question
I checked whether or not the assumptions for logistic regression analysis were met to
ensure that the data were suitable for this test. The assumptions include:
1. Presence of dichotomous dependent variable,
2. Presence of one or more independent variables,
3. Ensure that the observations are independent,
4. Ensure that the sample size is greater than 10 cases per variable (rule of thumb),
5. Non multi-collinearity (Laerd Statistics, 2013)
6. Normality.

Observing the data set, I noticed that the first four assumptions were met for the
following reasons. First, the dependent variable, the frequency of PrEP prescription was
transformed into a dichotomous variable (i.e., prescribe PrEP, coded yes and not
prescribe PrEP, and coded no. Second, I included in the study, one primary independent
variable (awareness about PrEP) and many secondary independent variables or covariates
(i.e., awareness of PrEP, years of experience, specialty, sex, age range, and location).
Third, the responses provided for each question about the independent variables were
independent of each other. Fourth, I observed more than ten (10) cases (i.e., 100 cases).
I ran a series of collinearity diagnoses to test for no multi-collinearity assumption.
The results are presented in Tables 13 and 14.
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Table 13
Collinearity Diagnosis for Multi-Collinearity (n = 100)

Model

Collinearity Statistics
Tolerance

VIF

.908

1.102

.997

1.004

.894

1.118

.985

1.015

Locations (Illinois versus Iowa)

What is your specialty?

Gender (Male versus Female)

Prescribe versus Not prescribe PrEP

Note. Tolerance > 0.10; VIF < 3
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Table 14
Collinearity Diagnosis for Multi-Collinearity of Frequency of PrEP (n = 100)
Model

Collinearity Statistics
Tolerance

VIF

.787

1.271

Locations (Illinois versus Iowa)

.901

1.109

What is your specialty?

.818

1.223

Gender (Male versus Female)

.856

1.168

Low awareness versus High
awareness

Note. Tolerance > 0.10; VIF < 3

For each collinearity analysis, the tolerance levels were very high (i.e., > 0.70),
hence, greater than 0.10, the minimum tolerance level that indicates a presence of multicollinearity. All VIF values were very low (i.e., around 1.1), hence less than VIF = 3,
considered as the minimum VIF value to conclude for the existence of multicollinearity
(Gaskin, 2011). Indeed, the assumption of no multicollinearity was met as well.
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I also run Kolmogorov-Smirnov test to check the normality of the model. I used a
stepwise (i.e., enter method) and incorporated all variables. The results showed p-values
= 0.00 for each of the variables. The p-value was less than 0.05, indicating that the
variables do not follow a normal distribution (Ghasemi & Zahediasl, 2012).
I transformed data using 1/x and x-squared. Next, I run Kolmogorov-Smirnov to
recheck the normality of the transformed data. The results were statistically significant,
showing that the sample does not follow a normal distribution. Consequently, logistic
regression model is not appropriate for the analysis.
Instead, I used Kendall’s Tau-b test (a nonparametric test) to analyze the research
question one and question two. I used it as an alternative to Spearman’s rank-order
correlation test whose monotonicity assumption was not met. Kendall’s Tau-b model, not
only measures the strength of association between binary variables, but also it indicates
the direction of the relationship (Laerd Statistics, 2013). The assumptions of Kendall’s
Tau-b test were met; because, I can observe that the variables were continuous, and
weighted on an ordinal scale. In addition, monotonicity is “not a strict assumption” for
the model (Laerd Statistics, 2013). In a cancer study, Yao et al. (2007) used Kendall’s
Tau-b test to find statistically “significant association between β1 integrin intensity score
and fibronectin expression (Kendall's tau-b = 0.19; P = 0.03)” (Yao et al., 2007).

Research Question 1
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What is the association between HIV PrEP awareness (independent variable) and
the frequency of PrEP prescription (dependent variable) among primary care providers
and HIV specialists in the Quad-Cities?
Ho1: There is no association between HIV PrEP awareness and the frequency of
PrEP prescription among primary care providers and HIV specialists in the Quad-Cities.
Ha1: There is an association between HIV PrEP awareness and the frequency of
PrEP prescription among primary care providers and HIV specialists in the Quad-Cities.

Research question one was tested using Kendall's tau-b correlation test to
determine the association between 100 physicians’ awareness of PrEP and the frequency
of PrEP prescription among primary care providers and HIV specialists. There was a
moderate, negative correlation between awareness of PrEP and the Frequency of PrEP
prescription, which was statistically significant, (τb = - .367, p < .001). The negative
value is an indication that the dependent variable and independent variable decrease
collectively (What is Kendall's tau-b, 2016). Explicitly, the frequency of PrEP
prescription decreases with the decrease of the physicians’ awareness about PrEP. I
presented the result in Table 15.
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Table 15
Kendall's tau-b Correlation Test of Association Detween Awareness of PrEP and PrEP
Prescription (n = 100)

Correlation
Low awareness versus

Coefficient

High awareness

Sig. (2-tailed)
N

Low

Prescribe

awareness

versus Not

versus High

prescribe

awareness

PrEP

1.000

-.367**

.

.000

100

100

-.367**

1.000

Kendall's tau-b
Correlation
Prescribe versus Not

Coefficient

prescribe PrEP

Sig. (2-tailed)

.000

.

N

100

100

**. Correlation is significant at the 0.01 level (2-tailed).
I reject the null hypothesis. There is an association between HIV PrEP awareness and the
frequency of PrEP prescription among primary care providers and HIV specialists in the
Quad-Cities.
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Research Question 2
What is the association between the number of years of service as a primary care
provider or HIV specialist and the frequency of PrEP prescription among primary care
providers and HIV specialists in the Quad-Cities?
Ho2: There is no association between the numbers of years of service as a
primary care provider and the frequency of PrEP prescription among primary care
providers and HIV specialists in the Quad-Cities.
Ha2: There is an association between the numbers of years of service as a primary
care provider and the frequency of PrEP prescription among primary care providers and
HIV specialists in the Quad-Cities.

A Kendall's tau-b correlation test was run to determine the association between
100 physicians’ years of experience and the frequency of PrEP prescription. The results
presented in Table 16 showed a weak negative correlation between years of service and
the Frequency of PrEP prescription, which was statistically significant (τb = - .228, p =
.010). The negative value shows that the frequency of PrEP prescription decreases when
the number of years of service as a primary care provider decreases.
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Table 16
Kendall's tau-b Correlation test of Association Between Years of Experience and PrEP
Prescription

Prescribe versus

How long have

Not prescribe PrEP you been served
as a physician?
1.000

-.228*

.

.010

100

100

-.228*

1.000

Sig. (2-tailed)

.010

.

N

100

100

Correlation
Prescribe versus
Coefficient
Not prescribe
Sig. (2-tailed)
PrEP
Kendall

N

's tau-b

Correlation
How long have
Coefficient
you been served
as a physician?

*. Correlation is significant at the 0.05 level (2-tailed).

I rejected the null hypothesis. There is an association between the numbers of years of
service as a primary care provider and the frequency of PrEP prescription.
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Research Question 3
What is the difference between provider types and the frequency of PrEP
prescription among primary care providers and HIV specialists in the Quad-Cities?
Ho3: There is no difference in provider types and the frequency of PrEP
prescription among primary care providers and HIV specialists in the Quad-Cities.
Ha3: There is a difference in provider types and the frequency of PrEP
prescription among primary care providers and HIV specialists in the Quad-Cities.

Fisher’s Exact test was used for research question 3 to examine whether there is a
difference in provider types and the frequency of PrEP prescription among primary care
providers and HIV specialists.
Checking for Fisher’s Exact Assumptions
I have a small sample size N = 100. The participants to the survey are independent
of each other. I also have two categorical variables and more than two groups (5 groups)
in the specialty category. Therefore, Fisher’s exact test assumptions were met.
For information, one-way Analysis of Variance (ANOVA) was projected to
analyze the research question three. However, the model did not fit because the
continuity assumption one was not met. The dependent variable (i.e., the frequency of
PrEP prescription) was not continuous. It was categorical that I changed it into binary
(high frequency/low frequency). I have more than two groups in the specialty category
and small cell counts in the categories. Therefore, I chose Fisher’s exact test to analyze
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the research question 3 over Kendall's tau-b correlation test that used to weight the
research questions one and two. The research questions 1 and 2 focus establishing the
association between the variables, and therefore align with Kendall’s Tau-b that “is a
measure of association” (Non-parametric Measures, n. d.). On another hand, the research
question 3 is about determining the difference in PrEP prescription among five
specialties; therefore, fit into Fisher’s exact model that determine the difference within
groups (Mehta & Patel, n. d.). Table 17 showed the cross-tabulation of the frequency of
PrEP prescription by specialty.
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Table 17
Cross Tabulation of the Prescription of PrEP across Specialty (n = 100)

Specialty

Count and Percent (%)

Prescribe versus Not prescribe PrEP
Prescribe PrEP

Count

Family Practitioner

Not prescribe PrEP

3

30

% within specialty

9.1%

90.9%

% within Prescribe versus

21.4%

34.9%

1

16

% within specialty

5.9%

94.1%

% within Prescribe versus

7.1%

18.6%

3

13

18.8%

81.3%

Not prescribe PrEP

Count

Pediatrician

Not prescribe PrEP

Count
Obstetrician/Gynecologist

(Table continues)

% within specialty

100

Specialty

Count and Percent (%)
% within Prescribe versus

Prescribe PrEP
21.4%

Not Prescribe PrEP
15.1%

Not prescribe PrEP

Count

4

14

% within specialty

22.2%

77.8%

% within Prescribe versus

28.6%

16.3%

3

8

% within specialty

27.3%

72.7%

% within Prescribe versus

21.4%

9.3%

14

86

% within specialty

14.0%

86.0%

% within Prescribe versus

100.0%

100.0%

Infectious diseases/HIV
Specialist
Not prescribe PrEP

Count

Internist

Not prescribe PrEP

Count

Total

Not prescribe PrEP

Note. Fisher’s Exact Test showed p = .130.
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I also presented the results in the bar chart in Figure 17.

Figure 17. Differences in the frequency of PrEP prescription across specialty.

Based on Fisher’s Exact test, there was no statistically significant difference at
0.05 significance level (p = .130). Therefore, I failed to reject the null hypothesis and
conclude that there is no difference in specialty and the frequency of PrEP prescription
among primary care providers and HIV specialists in the Quad-Cities. I summarized the
results of the three research questions in Table 18.
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Table 18
Summary of the results of the PrEP study (n = 100)

Research Questions

Statistical tests

Results

Conclusions

RQ1: What is the

Kendall's tau-b

There was a

I reject the null

association between HIV

correlation test

statistically

hypothesis. There is an

PrEP awareness and the

significant

association between HIV

frequency of

association.

PrEP awareness and the

PrEP prescription among

(τb = - .367, p <

frequency of PrEP

primary care providers

.001).

prescription among

and HIV specialists in

primary care providers

the Quad-Cities?

and HIV specialists in the
Quad-Cities

RQ2: What is the

Kendall's tau-b

There was a

I reject the null

association between the

correlation test

statistically

hypothesis. There is an

number of years of

significant

association between the

service as a primary care

association.

numbers of years of

(Table continues)
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Research Questions

Statistical tests

provider or HIV

Results

Conclusions

(τb = - .228, p = .010)

service as a primary care

specialists and the

provider and the

frequency of PrEP

frequency of PrEP

prescription among

prescription among

primary care providers

primary care providers

and HIV specialists in

and HIV specialists in the

the Quad-Cities?

Quad-Cities.

RQ3: What is the

Fisher’s Exact

No statistically

Null hypothesis is not

difference between

test

significant difference

rejected. There is no

P = 0.130

difference in provider

provider types and the
frequency of PrEP

types and the frequency

prescription among

of PrEP prescription

primary care providers

among primary care

and HIV specialists in

providers and HIV

the Quad-Cities?

specialists in the QuadCities.
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Summary
The majority of the respondents had low awareness of PrEP. The frequency of not
prescribing PrEP was very high. Ninety percent did not prescribe PrEP. About 60% have
never thought about prescribing PrEP. The lack of awareness of PrEP and the lack of
PrEP prescribing opportunities were the two primary reasons for physicians’ reluctance
to prescribing PrEP. For example, more than the half of the participants do not know
much about PrEP guidelines/protocol in order to prescribe or propose its services to the
patients. About one-third of them had never been in a situation that required prescribing
PrEP. Physicians who had higher awareness about PrEP prescribed it often compared to
those who know only little about. Based on the cross-tabulation analysis, the physicians
with many years of professional experience often prescribed PrEP. For example, the
highest frequency of PrEP prescription was found among the physicians that have 26 and
more years of experience, and the lowest frequency of PrEP prescription was found
among the physicians that have 0-5 years of experience. Furthermore, infectious disease /
HIV specialists prescribed more often PrEP. Physicians aged between 55 and 64 years
old and more, prescribed PrEP very often. Males more often prescribed PrEP compared
to females. Geographically, the frequency of PrEP prescription was almost equally
distributed across both Illinois and Iowa-Quad Cities areas.
Kendall's tau-b correlation analysis of the research question one showed a
statistically significant association between awareness of PrEP and the frequency of PrEP
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prescription (τb = - .367, p < .001). That of the research question two also revealed a
statistically significant association between years of experience and the frequency of
PrEP prescription (τb = - .228, p = .010). Regarding the research question three, Fisher’s
Exact test showed p = 0.130, meaning that there was no statistically significant difference
in provider types and the frequency of PrEP prescription among primary care providers
and HIV specialists in the Quad-Cities.
In Chapter 5, I discuss the interpretation of the findings and conclusion of the
results. I also discuss the limitations of the study, the implications for social change, and
end the chapter by suggesting recommendations for future research.
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Chapter 5: Discussion, Conclusions, and Recommendations
Introduction
In this survey study, I aimed to explore the barriers to prescribing HIV PrEP and
the need for education among care providers in the Quad Cities. The probability of
contracting HIV is high among people who live in serodiscordant relationships. Securing
a healthy sexual relationship was one of the top wishes of the serodiscordant sexual
partners or couples (Heitz, 2015). PrEP was revealed 96% operative to decrease the risks
of HIV infection in HIV-negative populations. However, the protocol of PrEP
prescription is understood, causing under prescription among primary care providers and
infectious diseases/HIV specialists (Carter, 2015). For these reasons, I proposed to test
the hypothesis that awareness of PrEP, years of experience in the medical field, and
provider types might be associated with the frequency of PrEP prescription among
primary care providers and HIV specialists. To assess the level of PrEP awareness, and
how often the care providers prescribe PrEP, I ran a series of frequency tests using SPSS.
I used Kendall's tau-b correlation test and Fisher’s exact test to analyze the research
questions. The findings showed that lack of awareness of and missing the opportunity to
prescribe PrEP were the two primary barriers to prescribing PrEP at the care providers’
level. Kendall's tau-b correlation test revealed that there was a statistically significant
association between awareness about PrEP and the frequency of PrEP prescription. The
relationship between the years of experience and the occurrence of PrEP prescription was
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also statistically significant. Fisher’s exact tests showed non-significant differences
between provider types and the frequency of PrEP prescription. In the following
discussion, I describe the findings, compare them to those from the previous studies, and
analyze them in the theoretical framework standpoint.
Interpretation of the Findings
I examined how HIV PrEP awareness, providers’ years of service, and provider
types could be used as predictors of the frequency of PrEP prescription. Many types of
research have been conducted on the barriers of prescribing PrEP at the client or patient
level. However, literacy on PrEP provision among primary care physicians and HIV
specialists is lacking. The findings of the dissertation research revealed a relationship
between awareness about PrEP and the frequency of PrEP prescription. I also found that
the relationship between the years of experience and PrEP prescription were statistically
significant. There is no statistically significant difference in provider type and the
frequency of PrEP prescription among primary care providers and HIV specialists in the
Quad Cities.
I discovered that the majority of respondents had low awareness about PrEP.
Rosenthal et al. (2013) also found that the majority of physicians were unaware of the
PrEP. Similar to Krakower and Mayer (2013), I found that PrEP was underprescribed
among primary care providers and infectious diseases/HIV specialists. I also discovered
that the frequency of PrEP prescription was high among those who have high awareness
of PrEP. These findings are similar to those of other studies conducted by Young et al.,
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(2013); Puro, et al., (2013); White et al., (2012). They found increased knowledge about
PrEP associated with the rise in the frequency of PrEP prescription among primary care
providers.
In light of the observations described above, primary care providers and
HIV/AIDS specialists’ disposition to prescribe PrEP depend on how much information
and knowledge they have about PrEP. Moreover, providers’ readiness to prescribe PrEP
and patients’ wiliness to adopt it should be the sine-qua-none conditions to promote PrEP
regimen in the Quad Cities. However, I did not explore patients’ attitudes towards, and
need of PrEP services in this study.
The findings disconfirmed the assumption that the frequency of PrEP prescription
is different as far as the physicians’ specialty. Furthermore, the results did not support the
hypothesis that there is a difference in provider types and the frequency of PrEP
prescription among primary care providers and HIV specialists. In addition, while
Hoberg and Raymond (2013) found that high cost of PrEP could dissuade its prescribers
and users, this study revealed that excessive cost and coverage of PrEP issues were not
the primary barriers of prescribing it. Finally, the findings were opposite of the findings
of Puro et al. (2013) that demonstrated that only HIV/AIDS specialists had a privilege to
prescribe PrEP. In fact, this study showed that even non-HIV/AIDS specialists (i.e.,
family practitioners, internists, obstetricians/gynecologists, and pediatricians), had
prescribed PrEP.
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This study adds to the body of public health knowledge through the discovery that
lack of awareness about PrEP and lack of opportunity are the primary barriers to
prescribing PrEP at the physicians’ level. It provides insights that males are more likely
to prescribe PrEP than females. It also shows equal distribution of the frequency of PrEP
prescription across Illinois and Iowa.
Theoretical Framework
The principles of the PAPM as applied to this study include (a) identification of
the seven stages of PAPM where physicians went through when prescribing PrEP and (b)
definition of the factors that stimulate their movement from one stage to another. The
results of the survey provided information on the physicians’ attitudes corresponding to
each stage of the constructs of PAPM. I observed the following:
The majority of the respondents have never thought about prescribing PrEP (Stage 1:
unaware).
1. Twenty-three percent of respondents were unresolved about prescribing PrEP
(Stage 3: undecided).
2. Thirteen percent have decided that they want to prescribe PrEP (Stage 5:
decided to act).
3. Three percent have declared “do not want to prescribe PrEP” (Stage 4:
decided not to act.), and
Two percent have no opinion of prescribing PrEP. Here are some possible
interpretations:
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Stage 1: Unaware
About one-fifth of the physicians had never heard of PrEP. Therefore, they would
never prescribe PrEP. There is a need for basic information (education) on PrEP to allow
them to move to the next stages.
Stage 2: Unengaged
About 70% of the participants learned very little or a little about PrEP. However,
they were not yet engaged due to underprescribing PrEP. Targeted education is desirable
to make PrEP and the need for action personally important to unengaged physicians.
Stage 3: Undecided
About a quarter of the surveyed physicians were undecided about prescribing
PrEP, meaning that they were engaged with the issue and looking for how to proceed.
Since they did not yet form an opinion about prescribing PrEP, they would be less
resilient to persuasion (DiClemente, Crosby, & Kegler, 2002). Therefore, technical
training is necessary for undecided physicians.
Stage 4: Decided Not to Act
Less than 5% of the surveyed physicians said that they do not want to prescribe
PrEP. I assumed these people were aware of PrEP but have unexpressed reasons that
challenge their decision to prescribe it. DiClemente et al. (2002) stated that those
individuals might be difficult to persuade, and the precaution adoption process ends there.
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On the other hand, some may hold off on deciding and stay undecided (Stage 3).
Proactively identifying these barriers to PrEP education programs could help health
educators to develop suitable strategies to overcome them.
Stage 5: Decided to Act
About 15% of the participants said that they plan to prescribe PrEP. I assumed
that these individuals were conscious of the risks for not prescribing PrEP and the
outcomes. Therefore, they decided to prescribe it. I used the data as baseline information
to measure the percentage of physicians who are ready to prescribe PrEP in the Quad
Cities area.
Stage 6: Acting
Ten percent of the surveyed physicians are prescribing PrEP. I also assumed that
they might have some intrinsic and extrinsic motivations that I did not examine.
Refreshment PrEP training might be needed to empower that target populations to
continue prescribing PrEP
Stage 7: Maintenance
The study did not provide relevant data to quantify the number of physicians who
have maintained their prescribing of PrEP over time. Further investigation of this aspect
of PAPM is desirable.
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Limitations of the Study
The physicians surveyed in this study did not represent a sample of all care
providers that can prescribe PrEP in the United States. It included family practitioners,
infectious disease/HIV specialists, internists, obstetricians/gynecologists, and
pediatricians only. I might expand the sample to include other medical specialties such as
physician assistants and certified nurse practitioners. Furthermore, the answers to the
questions could be biased because of the self-reported survey (Yu & Tse, 2012). By
aligning the survey questions strictly to the study’s theoretical framework context, I
missed the opportunity to include a question that will help me to quantify the need for
PrEP education among physicians with exactitude. I wish I added the following “yes” or
“no” question to the survey questions: Do you want to learn more about PrEP? By
default, I determined the need for PrEP education based on inference to answer b of the
following survey question, “What is the most accurate reason why you may not prescribe
or propose PrEP services to your clients who might need them?” (Please check one). I
assumed that every participant who selected answer b, “I don’t know much about PrEP
and its guidelines/protocol to prescribe or propose its services to my clients,” has
implicitly expressed, a need for PrEP education. Therefore, the data may be misreported.
The results of the pilot test of the survey instrument provided evidence that supports the
reliability of the data collection tools.
In Chapter 2 related to the literature review, I failed to report that the efficacy of
the PrEP usage matches that of usage of condoms (Thompson, April 2014). Because the
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usage of condoms only could not end HIV/AIDS pandemics, Thomson (2014) stated,
“We have already lost the battle in condom use … condoms fatigue” (p.19). Therefore, a
PrEP regimen that integrates steady and correct usage of condoms is recommended to
prevent HIV transmission.
The findings both confirmed and disconfirmed many results from the literature
review on the concepts and key variables. For example, this study revealed the need for
PrEP education and literacy improvement for physicians. Likewise, Krakower and Mayer
(2012) showed that PrEP education enhancement within care providers is desirable to
limit the higher HIV infection incidence rate in the United States. The findings also
indicated that the majority of physicians do not prescribe PrEP because they do not know
about its protocol. This confirms foundings from White et al. (2012) that 96% of
physicians believed that formal PrEP guidelines from the CDC would increase their
readiness to prescribe PrEP. Similar to results of the literature review, this study revealed
that PrEP was understood among primary care providers (Rosenthal et al., 2013).
Whereas the literature review demonstrated the effectiveness of PrEP
(Choopanya, et al., 2013; Paltiel et al., 2009), this study was limited to investigating the
variance in the frequency of PrEP prescription among physicians. The literature review
also found an association between stigma and PrEP prescription (Smith et al., 2012).
However, I did not include stigma in the key variables of this study.
In relation to inferences from the research data, the participants were randomly
selected as well as engaged from different hospitals to ensure the generalizability of the
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study (Creswell, 2009). Therefore, the study can be generalized to other care providers
nationally and worldwide. Furthermore, the pilot tested survey instrument could become
a reference for future researchers.
Recommendations for Action and Future Study
This research established a statistically non-significant difference in provider
types and the frequency of PrEP prescription among the physicians from the five
specialties engaged in the study. Therefore, I would recommend a study that includes
other specialties or groups, such as physician assistants and nurse practitioners that can
prescribe PrEP. I would also suggest using the odds ratio analysis to determine whether
the probabilities of prescribing PrEP are similar for primary care providers and HIV
Specialists. The actual study includes very small sample size. I would propose a
quantitative study involving a large sample size. To better understand the barriers to PrEP
prescription, I would suggest qualitative research through interviews and focus group
discussions targeting physicians from different settings. Further implementation research
may be needed to understand and improve PrEP delivery at local and state levels. I would
recommend using the results of this study to support or justify PrEP education and
implementation grants projects. The findings can also inspire policies to regulate and
update HIV/AIDS structural interventions. For example, it may be necessary to develop
policies that support integrated PrEP implementation strategies. The strategies could
consist of using HIV test to inform on PrEP, adding PrEP to risk assessment counseling
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process, and integrating PrEP referrals into partner services, STD clinics, and social
network strategies.
As a call for action to improve the frequency of PrEP prescription, I would
recommend the following:


Create a PrEP center in the Quad Cities area and wherever there is a need to better
identification of, and response to, under-prescribing of PrEP gaps;



Develop a comprehensive PrEP education curriculum that aligns to the precaution
adoption process model for care providers nationwide;



Include PrEP topics into the continued education online training modules for all
physicians, physicians assistants, and nurse practitioners;



Develop policies that support integrated PrEP implementation strategies. The
strategies could consist of using HIV test to inform on PrEP, adding PrEP to risk
assessment counseling process, integrating PrEP referrals into partner services,
STD clinics, and social network strategies, and



Educate and train providers including case managers, outreach staff, and testing
counselors about PrEP guideline, PrEP protocols, its advantages and limits.

Finally, I would suggest taking PrEP information beyond care providers to the
community as large trough community forums, community outreaches, seminaries, peer
education, and webinars.
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Implications for Social Change
This study is of public health interest. By empowering care providers to prescribe
PrEP more often to vulnerable populations including sex workers, persons in a
serodiscordant relationship and others, the study will bring positive changes to
individuals and their families. The direct impacts could include peace of mind and
elimination of fear of the HIV infection. PrEP will not only bring new dynamics (i.e.,
confidence, psychological supports, love, harmony, sexual freedom, etc.) in the family of
serodiscordant individuals but will also prevent new infections. Next, providing PrEP to
the professional sex workers and multiple sex partners will reduce HIV infection in the
community. At the organizational level, the study could add value to the public health
educators’ efforts to advance the population health. It provides empirical data and a
theoretical framework that HIV/AIDS prevention and treatment agencies/organizations
can use for different purposes. Further, this study presents PAPM, as a potential
evidence-based theoretical framework for the future PrEP interventions. The
methodological approach could be a reference for many researchers, health educators,
HIV/AIDS organizations and other public health professionals to advance research in the
field.

Conclusion
Statistical analyses showed that there is an association between Prep awareness
and frequency of PrEP prescription. However, if this study had identified an association
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between awareness of PrEP and the frequency of PrEP prescription, may have been
increased with the high PrEP awareness. I rejected the null hypothesis that “there is no
association between the numbers of years of service as a primary care provider and the
frequency of PrEP prescription among primary care providers and HIV specialists in the
Quad-Cities” too. Therefore, the number of years of service as a primary care provider
and the frequency of PrEP prescription were associated. The unknown was the maximum
number of years of experience as a standard to predict the outcome of PrEP prescription
among primary care providers and HIV specialists.
I found no difference in provider type and Prep prescription. Infectious diseases
and HIV/AIDS specialists prescribed PrEP more often than other specialties. About onethird of HIV/AIDS frontline care providers have few opportunities to prescribe PrEP;
whereas many other physicians are missing these chances in the United States (Carter,
2015). The majority of doctors including family practitioners, internists,
obstetricians/gynecologists and pediatricians had low awareness about PrEP. They had
differences of opinion and practice regarding PrEP prescription. Primary care physicians
believed that it was HIV/AIDS specialists’ responsibility to prescribe PrEP. Inversely,
HIV/AIDS specialists thought that PrEP is a preventive approach and should be handled
by primary care physicians.
In the absence of an HIV vaccine, PrEP could become an indispensable tool to
prevent HIV infection. Therefore, it is urgent to scale up PrEP prescription across the
United States and beyond by creating adequate infrastructures for PrEP provision and by
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providing continued PrEP training to health care professionals. It is also important to
provide physicians appropriate tools to detect persons at-risk for HIV infection, and
encourage them to prescribe PrEP more often to these vulnerable persons. Ultimately, the
results of this study indicate that physicians need education and training to fully
understand the potential of PrEP to reduce HIV transmission in the Quad Cities area.
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Appendix A : Pilot Project Survey Questionnaire

PART 1 – DEMOGRAPHIC INFORMATION
The information that you provide is only for statistical drive. I will remain confidential
and anonymous. Your participation will be highly appreciated.
1. Your area Zip Code is
…………………………………………………………………….
2. Your Gender (Please, circle one)
-

Male

-

Female

3. What is your age? (circle that applied)
-

18 to 24

-

25 to 34

-

35 to 44

-

45 to 54

-

55 to 64

-

65 to 74

-

75 or older

PART II – QUESTIONS ON HIV PrEP AWARENESS
1) Tell me the number that shows how much you know about HIV Pre-Exposure
Prophylaxis (PrEP). (Please, circle that is applied to you.)
1. Very much

5. Very little

2. Much

6. None
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3. Quite a bit

7. Don’t know

4. A little

8. No answer

TART III – QUESTION ON HIV PrEP PRESCRIPTION FREQUENCY
2) Tell me the number that shows how often you prescribe HIV PrEP. (Circle that is applied
to you.)
1. Very often

5. Very little

2. Often

6. None

3. Quite a bit

7. Don’t know

4. A little

8. No answer

PART IV – QUESTION ON THE YEAR OF SERVICE AS A PRIMARY CARE
PROVIDER OR A HIV SPECIALIST
3) How long have you being served as a primary care provider or a HIV specialist? (Circle
the group that is applied to you.)
a) 0 to 5 years
b) 6 to 10 years
c) 11 to 15 years
d) 16 to 20 years
e) 21 years and more
PART V – QUESTION ON THE SPECIALTIES
4) Circle all that applied to you:
a) I am a family practitioner.
b) I am a pediatrician.
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c) I am an internist.
d) I am an-obstetricians/gynecologists.
e) I am an infectious disease specialist
f) I am a HIV specialist
g) Other (please, precise) ……………………………………………………………….
PART VI – QUESTIONS ON HIV PrEP PRESCRIPTION ATTITUDE AND BARRIERS
5) Which of the following best describes your thoughts about prescribing PrEP? (Circle that
is applied)
a) I have never thought about prescribing PrEP to clients.
b) I am undecided about prescribing PrEP to clients.
c) I have decided I do not want to prescribe PrEP to clients.
d) I have decided I do want to prescribe PrEP to clients.
6) Select the most accurate reason (only one) why you might not prescribe or propose HIV
PrEP services to your clients who might need it from the following:
a) I have never been in a situation that required me to prescribe or propose HIV PrEP
services to a client.
b) I don’t know much about PrEP and its guidelines/protocol to prescribe or propose its
services to my clients.
c) I think that only HIV specialists can prescribe HIV PrEP.
d) Insurance companies don’t want to cover HIV PrEP for my clients.
e) Clients and or I have concerns about the HIV PrEP drugs’ side effects.
f) My clients cannot afford HIV PrEP services because of the high cost.
g) I have no reason.
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